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1General Introduction
1
9Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic disease, with a course 
that is difficult to predict, varying from mild to very severe. When the disease is active, 
patients with RA experience pain and swelling in affected joints and can have joint 
stiffness especially in the morning. The disease has great influence on functional 
ability, fatigue and quality of life. Since there is no definite cure for the disease, the 
goal of pharmacotherapy is to achieve and maintain low disease activity, and 
consequently to prevent the progression of joint destruction and functional disability 
(1).  
 
Current treatment of RA 
Patients with rheumatoid arthritis are usually treated with a combination of different 
drugs (1,2). Almost all patients are treated with one or more ‘disease modifying anti-
rheumatic drugs’ (DMARDs) to control the disease process and slow the progression 
of the disease. Usually a ‘non-steroidal anti-inflammatory drug’ (NSAID) is added to 
control symptoms. Sometimes corticosteroids are used in addition, to bridge flares or 
as maintenance therapy.  
Since DMARDs control rather than cure the disease, the management of RA is 
an iterative process, and patients should be periodically monitored for evidence of 
disease activity or progression and for any toxic effects of the treatment regimen. If 
necessary, treatment should be adjusted accordingly. Patients may also benefit from 
education about their disease, consultations with physical therapist and social workers 
and treatment is therefore multidisciplinary (1). When joints are severely destructed 
by the disease, orthopedic surgery is an option. 
 
A historical perspective of RA drug treatments 
The course of disease activity in RA patients has become milder in recent years (3). 
The reason for this trend is not exactly clear, but the trend coincides with a more 
aggressive treatment strategy nowadays. All available DMARDs were developed in the 
20th century. Figure 1 displays the historical context of the development of all 
DMARDs. It can be noticed that in the earlier years gold agents and corticosteroids 
were the most important drugs. From the 70’s and the 80’s onwards, sulfasalazine and 
methotrexate have been widely used. Nowadays, a combination of these two drugs is 
used as the first line treatment for newly diagnosed RA patients (4). However, most of 
the DMARDs were found to be effective from empiricism or serendipity whereas their 
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mechanisms of action remains unclear. A minority of DMARDs was developed on the 
basis of the pathophysiology as currently understood, whereas the most recently 
introduced biological treatments, like TNFα blocking agents, were.  
 
TNFα blocking agents 
The TNFα blocking agents specifically target the cytokine tumour necrosis factor 
alpha (TNFα). Adalimumab and infliximab are monoclonal antibodies, whereas 
etanercept is a soluble receptor blocking TNFα. TNFα blocking agents have proven to 
be efficacious in several clinical trials (5-7) and have changed the treatment of patients 
with RA tremendously. Because the development of these agents is based on the 
pathophysiology as currently understood, they are perceived as a revolution in the 
treatment of RA. Other ‘biological’ treatments, like anti-IL1, anti-B-cell therapy and 
therapies targeting T-cells are introduced and many more of these agents are in the 
pipeline of drug developers. 
 
Figure 1: A historical perspective of drugs in rheumatoid arthritis 
 
This figure is based on the text from the reviews by John Case (8,9) 
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Forestier et al pioneered the use 
of  Gold salts in RA in 1929
In 1938 Svartz et al developed 
Sulfasalazine. However, it is 
widely used since the 70s.
In 1949 glucocorticoids 
were introduced for RA by 
Hence et al, who received 
the Nobel Prize for it in 
1950. 
Gubner et al showed the effectiveness 
of  methotrexate or RA in 1951. 
However, it is widely used since the 80s.
Antimalarials (e.g. Hydroxuchloroquine) 
were shown to be effective in RA.
Cytotoxic agents were started to 
being used for RA; azathioprine 
in the early 60s and 
cyclophosphamide in the 70s
The effectiveness of  d-penicilamine 
was published first in 1973
The first use of  cyclospirine
Leflunomide is being 
developed in 1985 and was 
first used in 1991. The FDA 
approved the drug in 1998
The pivotal role of  TNFα  in the pathogenesis 
of  RA is shown in 1991. Nowadays three TNF 
α blocking agents are approved in the 
Netherlands: etanercept (2001), infliximab 
(2001) and adalimumab (2003)
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Costs of TNFα blocking agents 
Nowadays, TNFα blocking agents are widely used in the treatment of RA. Based on 
the prevalence and incidence of RA patients being treated with TNFα blocking agents 
and the predicted duration of usage of these drugs, it was estimated that 9974 RA 
patients would be treated with TNFα blocking agents in spring 2008 (10). This equals 
37% of the prevalence of RA patients in the Netherlands. In the Dutch health care 
system, 5.5 billion Euros is spend on drugs each year (11). A treatment with an TNFα 
blocking agent is relatively expensive, with mean medication costs of approximately 
1000 Euros per month. On the basis of the above-mentioned prevalence of RA 
patients using TNFα blocking, 1,8% of the national drug budget needs to be allocated 
to TNFα blocking agents for RA patients in 2008. Furthermore, the total amount of 
costs that is spend on two of the biological drugs for RA (adalimumab and etanercept) 
is increasing excessively as can be seen in the Table.  
 
Table: Top 10 in the Netherlands of extramural drugs with the highest increase in total 
expenditure in the first half of 2007 compared to the first half of 2006. 
  Total costs Absolute increase Increase 
 in terms of percentage 
1 Adalimumab (Humira ®)  38.180.700 10.366.200 37.27% 
2 Simvastatine (Zocor ®)  41.860.200 6.705.800 19.08% 
3 Atorvastatine (Lipitor ®)  90.667.600 5.729.500 6.75% 
4 Etanercept (Enbrel ®)  41.373.600 5.364.000 14.90% 
5 Somatropine (Norditropin ®)  26.720.500 4.528.800 20.41% 
6 Allergeenextracten  22.845.300 4.522.000 24.68% 
7 Esomeprazol (Nexium ®)  34.350.000 4.139.300 13.70% 
8 Salmeterol (Seretide ®)  66.158.800 4.122.000 6.64% 
9 Formoterol (Symbicort ®)  31.218.800 4.103.500 15.13% 
10 Pantoprazol (Pantozol ®)  53.925.400 4.097.000 8.22% 
Source: Drug Information System on extramural drug (not containing infliximab) of the Health Care 
Insurance Board 
 
In general, because we spend nowadays as a society a large amount of money on new 
(biological) drugs, it is aimed for efficient usage of these drugs. Efficient use is 
characterised by appropriate drug-prescribing patterns and adherence to these drugs 
resulting in health benefits where no additional health-care resource utilization is 
needed and productivity loss is reduced, thereby resulting in long-term economic gain 
(12).  
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To realise an efficient allocation of resources, pharmaco-economic data are 
required for making decisions about the reimbursement of drugs in many European 
countries (See Figure 2). Often, these pharmaco-economic data are results from 
decision analytic modelling studies. In general, models are limited reflections of real 
world behaviour and depend highly on the quality of the data used as input. Input 
originates often from randomized controlled trials (RCT) and assumptions are made 
concerning doses and duration of drug use in daily clinical practice. The RCT, as an 
experimental design, is the gold standard in showing the efficacy of a new drug 
because of the high internal validity. However the controlled setting of a RCT with 
stringent in- and exclusion criteria is often not a good representation of daily clinical 
practice. Therefore, the external validity of RCT data and consequently pharmaco-
economic models based on those data are questioned (13-17).  
 
Figure 2: Local regulations for reimbursement with regard to cost-effectiveness data 
 
 
Norway:
Pharmacoeconomic data
required for reimbursement; 
official guidelines in 
operation.
Finland:
Pharmacoeconomic evidence mandatory for evaluating new
therapies for reimbursement and may also be requested for 
existing therapies.
Sweden:
Cost-effectiveness data required 
for reimbursement.
Denmark:
Cost-effectiveness data may be requested for 
reimbursement decisions.
Britain:
National Institute of Clinical 
Excellence (NICE) evaluates
the cost effectiveness of 
medicines. Guidelines updated 
April 2004.
Germany:
Guidelines prepared. 
Institute for Quality and 
Efficiency in the Health 
Service established in 
2004.
France:
Not a formal requirement but 
increasingly used in 
reimbursement decisions. 
Guidelines prepared.
Spain:
Health technology 
assessment at a 
regional level.
Portugal:
Cost-effectiveness data 
incorporated 
into reimbursement decisions.
Italy:
Cost-effectiveness considered in 
pricing and reimbursement 
decisions. Greece: Guidelines for pharmacoeconomic studies 
prepared; cost-effectiveness data may be requested.
Belgium: 
Formal requirement for economic 
evaluation.
Netherlands:
Pharmacoeconomic evidence explicitly 
required for reimbursement of new 
products.
Ireland: Guidelines for 
pharmacoeconomic 
studies prepared; cost-
effectiveness data may 
be requested.
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As a result, some reimbursement authorities are considering to use results from real-
world data to facilitate policy decisions on coverage and payment (18-20). In the 
Netherlands, authorities are developing a new legislation for reimbursement decisions 
(21). A provisional license for reimbursement will be provided on the basis of a 
favourable outcome in a pharmaco-economic modelling study or a pharmaco-
economic study alongside a RCT. Thereafter, additional pharmaco-economic 
information needs to be collected in clinical practice over three years including real-
life drug survival, effectiveness and costs based on true doses. As a pilot study, the 
Dutch National Health Insurance Board funded a daily clinical practice registration in 
the field of rheumatology, which resulted in the Dutch Rheumatoid Arthritis 
Monitoring (DREAM) registry.  
 In this multi-centre registry every patient who starts on one of the TNFα 
blocking agents has been included since February 2003. The aim of the registry was to 
evaluate effectiveness, toxicity and use of TNFα blocking agents in patients with RA in 
daily clinical practice. Patients were not randomised between different anti-TNFα 
agents and treatment was at the discretion of the attending rheumatologists. 
 
Objective of this thesis 
The objective of this thesis is to explore the value and the validity of data collected in 
daily clinical practice for drug evaluation and cost-effectiveness studies, using data on 
TNFα blocking agents in rheumatoid arthritis. First, the need for information from 
daily clinical practice was researched in the first two chapters. Then, the value of daily 
clinical practice data was illustrated by answering two clinical research questions 
using the daily clinical practice data. To collect data in daily clinical practice on a large 
scale, a good and easy to use evaluation instrument is needed. It was recently 
suggested to use patient self-reported measures to monitor patients and to evaluate 
results from therapy. The last two chapters of this thesis address the possible problem 
of response shift that can bias the results of such self reported measures and the 
possibility to correct for the occurrence of response shifts.  
 
Current evidence for cost-effectiveness of TNFα blocking agents 
Chapter 2 gives a review of the published pharmaco-economic data that was used by 
authorities in several countries to base their decision on about reimbursement of 
TNFα blocking agents for RA. It was shown that a wide variety of pharmaco-
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economic model structures and data input was used for several pharmaco-economic 
modeling studies, leading to a wide range of cost-effectiveness ratios (€26000 to 
€164000 per QALY gained). Therefore, the results of pharmaco-economic modeling 
studies of the same drug with the same indication may vary considerably, 
complicating sound decision making. 
 
External validity of RCT data 
In Chapter 3, the efficacy of anti-TNFα agents for RA patients was compared between 
RCTs and daily clinical practice data to illustrate several issues concerning the 
external validity of RCT-data. There is a belief that effects in daily practice 
(effectiveness) generally are lower than effects in RCTs (efficacy), partly because 
patient populations differ. Therefore, it was hypothesized that when involving the 
daily clinical practice patients who had a disease activity high enough to be eligible for 
the trials, the effects of anti-TNFα agents would be similar in RCTs and practice. 
 
Clinical research questioned answered with daily clinical practice data 
In Chapter 4 and 5 two clinical research questions were answered with the use of daily 
clinical practice data in order to illustrate the value of these data. First (Chapter 4), 
the three TNFα blocking agents were compared in daily clinical practice on major 
outcomes like, disease activity, functionality, quality of life and costs. Two meta-
analyses compared the response percentages of the three TNFα blocking agents using 
data of published RCTs (22,23) and showed no difference in effectiveness. However, 
as mentioned earlier, the response observed in RCTs can be different from the 
response achieved in daily clinical practice (24,25). Therefore, a comparison between 
anti-TNFα treatments in daily clinical practice provides additional information to 
meta-analyses of RCTs.  
The second clinical research questioned that was evaluated in daily clinical 
practice was about a stopping rule in case of a non-response on anti-TNFα after three 
months of use. The guidelines in several European countries (26) and in the USA (27) 
for the use of anti-TNFα treatment advise that treatment should be discontinued in 
case of a non-response. In Chapter 5, We studied whether rheumatologists adhere to 
the Dutch guidelines for anti-TNFα treatment. Furthermore the consequences on 
disease activity, functionality, quality of life and costs were compared between patients 
who were and were not treated according to the guidelines. Chapter 5 also discusses 
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the efficiency of several variations on the present guideline, researching the best ratio 
between successfully and unsuccessfully treated patients.  
 
The use of self-reported measures as an measurement instrument 
Currently, the evaluation of effectiveness of anti-TNFα in daily clinical practice 
depends largely on measurement with the disease activity score (DAS28). The DAS28 
is a combined measure of a tender and swollen joint count of 28 joints, the 
Erythrocyte Sedimentation Rate and a patient general health perception (28). 
However, the DAS28, and in particular the joint count, is criticised for a low inter-
observer variability(29), the discrepancy with physician judgement (30) and the time-
consuming joint counts (31). Recently, it was suggested to use only self-reporting 
instruments instead of physician assessed disease activity, to evaluate results of drug 
therapy in clinical trials, observational studies and in clinical practice (32,33). The 
rationale for the use of self-reporting instruments is that the ability to discriminate 
between responders and non-responders is good and the instruments are very easy to 
apply(34).  
In general, it is a prerequisite of a measurement that the patient’s concept of the 
subject of measurement is the same in all situations. In self reporting instruments, 
patients rate their own health in reference to the representation of their current 
health. However, this representation of current health can differ between patients and 
within patients over time (35-48). This can lead to different valuations of the same 
health state at different moments in time. This phenomenon is often referred to as 
response shift (48).  
The aim of Chapter 6 was to research the occurrence of a response shift in RA 
subjective measures by exploring the association between objectively measured 
clinical status (as measured by the DAS28 excluding the VAS general health) and 
subjective perception of health in patients with RA. When a patient is newly 
diagnosed with a disease, coping and consequently adaptation to the disease is 
probably barely present. In that case, the perception of health is likely to be associated 
with the objectively measured clinical status. Later in the disease course, the 
symptoms can still be present, but the patient is better able to cope with them. 
Therefore, the hypothesis was tested that later in the disease course the perception of 
health is better than one would expect on the basis of the disease activity of the 
patient, compared to shortly after diagnosis. 
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Correcting for response shifts 
Some authors suggest that self-reported outcomes should be corrected for changes in 
relative standards (49,50) by for instance a then-test (49). Administering a then-test, 
patients are asked to re-rate, for instance, the baseline health state at the moment in 
time that the follow-up measurement takes place. Subsequently, the follow-up rating 
is compared with this then-test rating as a corrected baseline rating. It is convincingly 
shown that patients, who improved on their health, re-assess (with a then test) a 
former health state to be worse than actually initially rated(51). However, we reasoned 
that in order to correct health ratings by means of a then-test, this response shift 
should also be present in patients who deteriorate on their health (instead of 
improvement), a reasoning that is supported by prospect theory (52). However, sound 
evidence for this assumption has not been reported in literature. The aim of Chapter 
7 was to explore the relationship of shifts in internal standards with the direction of 
disease change in patients with severe and prolonged rheumatoid arthritis. 
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ABSTRACT 
 
Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic disease. Over the last 
decades the treatment (strategy) for this disease has changed dramatically: treatment 
has become more aggressive and new drugs have become available. Furthermore, 
closely monitoring the disease and treatment has been advocated. Rheumatoid 
arthritis has an extensive impact on quality of life and the costs for society of the 
disease are high. Since RA is a chronic disease with life long treatment, the long-term 
assessment of cost-effectiveness of new treatment (strategies) frequently implies 
modeling. This paper reviews the assessment of the diagnosis, the disease process and 
outcome including quality of life and costs and the methodology of cost-effectiveness 
(modeling) studies in RA. Furthermore it describes recent trends in the treatment of 
RA and summarizes current evidence regarding the effects on quality of life, costs and 
costs effectiveness of these new treatment strategies. Since traditional DMARD 
treatment is not expensive, early aggressive treatment with these drugs is probably 
cost-effective since these strategies do not seem to result in extra toxicity and are 
usually found to be effective. Also closely monitoring patients, if effective, is probably 
cost-effective. The exact place (i.e. as a first, second or third line drug) of the new 
drugs for the treatment of rheumatoid arthritis remains somewhat controversial, since 
cost-effectiveness analyses have varying results and methodology. Expected future 
developments in the field are discussed. 
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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic disease. The disease 
mainly affects the joints, but other organ systems can be involved. The joint 
involvement is mainly characterized by symmetric synovitis resulting in the 
destruction of cartilage and/or bone (1). RA is a heterogeneous disease with an 
unpredictable course, varying from a mild to a very severe and disabling disease (2-4). 
The exact etiology of RA is unknown, although there are several hypotheses including 
genetic and environmental factors (5) 
 
EPIDEMIOLOGY 
 
The incidence has been estimated at about 0.2 per 1000 in males and 0.4 per 1000 in 
females (6,7). The incidence of RA increases with age until the middle 70s, thereafter 
the incidence seems to decline. The prevalence is usually reported to be between 0.5 
and 1% with a female excess between 2 to 4 times (7). 
It has been suggested that the incidence of RA decreases (8,9) and that RA is 
becoming a milder disease (10-12). This might be related to changes in treatment 
strategy, or to changes in the disease itself due to for instance environmental factors. It 
may also be related to changes in the healthcare system (i.e. earlier/more frequent 
referral to rheumatologists) or due to study design (changes in inclusion criteria for 
clinical studies). 
Rheumatoid arthritis is associated with an excess mortality of about 25% and 
the main cause of death in this population is cardiovascular morbidity, which is 
increased in RA patients (13-15). 
 
DIAGNOSIS 
 
To classify RA the 1987 ACR criteria for RA have been developed (table 1) (16) These 
include morning stiffness the involvement of 3 or more joints, the involvement of 
hand joints, symmetric joints being involved, the presence of rheumatoid nodules, the 
presence of serum rheumatoid factor, and radiographic changes. If a patient fulfills 4 
of 7 criteria, a patient is classified to have RA. However these criteria might not be 
definitive early in the disease, as the subsequent course may indicate other diseases. 
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Furthermore not all patients satisfy these criteria at presentation and they may only 
satisfy these criteria over time. Therefore for the diagnosis of RA the ‘golden standard’ 
is still a physician diagnosis (17).  
 
Table 1: 1978 ACR criteria for the classification of RA 
Table 67.1 The 1987 ARA Criteria (Traditional Format) 
1. Morning stiffness Morning stiffness in and around the joints, lasting 
at least 1h before maximal improvement 
2. Arthritis in three or 
more joint areas* 
Softtissue swelling or fluid (not bony overgrowth) 
observed by a physician, present simultaneously 
for at least 6 weeks 
3. Arthritis of hand joints Swelling of wrist, MCP or PIP joints for at least 6 
weeks 
4. Symmetric arthritis Simultaneous involvement of the same joints 
areas (defined in 2) on both sides of the body 
(bilateral involvement of PIP, MCP or MTP joints 
is acceptable without absolute symmetry) for at 
least 6 weeks 
5. Rheumatoid nodules Subcutaneous nodules over bony prominences, 
extensor surfaces or in juxta-articular regions, 
observed by a physician 
6. Rheumatoid factor Detected by a method positive in fewer than 5% of 
normal controls 
7. Radiographic changes Typical of RA on posteroanterior hand and wrist 
radiographs; it must include erosions or 
unequivocal bony decalcification localized in or 
most marked adjacent to the involved joints (OA 
changes alone do not qualify) 
*Possible areas: right or left PIP, MCP, wrist, elbow, knee, ankle, MTP. 
At least four criteria must be fulfilled for classification of RA;  
patients with two clinical diagnoses are not excluded. 
© www.rheumtext.com – Hochberg et al (eds) 
 
TREATMENT 
 
Since there is no definite cure for the disease, the goal of pharmacotherapy is to 
achieve and maintain low disease activity, and to prevent the progression of the 
disease and the resulting joint destruction, functional disability and pain (18).  
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There are several strategies for the treatment of RA patients (18,19). Patients 
with rheumatoid arthritis are usually treated with a combination of different drugs. 
Almost all patients use a ‘non-steroidal anti-inflammatory drug’ (NSAID) to control 
symptoms. Usually a concurrent treatment with a ‘disease modifying anti-rheumatic 
drug’ (DMARD) is necessary to control the disease process and slow the progression 
of the disease. Sometimes corticosteroids are used in addition.  
Since DMARDs control rather than cure the disease, the management of RA is 
an iterative process, and patients should be periodically reassessed for evidence of 
disease activity or progression and for any toxic effects of the treatment regimen. If 
necessary, treatment should be adjusted accordingly.  
Recently new drugs have been introduced for the treatment of rheumatoid 
arthritis, mainly the DMARD leflunomide and the ‘biologicals’, which specifically 
target the cytokines involved in the chronic inflammation (20-23). Patients may also 
benefit from education about their disease, consultations with physical therapist and 
social workers and treatment is therefore multidisciplinary (18). When joints are 
destructed by the disease, orthopedic surgery might be an option. 
 
(CLINICAL) ASSESSMENT OF RA 
 
Table 2: Core set of efficacy endpoints for RA clinical trials 
 
 
 
 
 
 
 
 
 
 
 
To evaluate the disease course and the effectiveness of treatment several 
measurements exist but there is no golden standard for ‘disease activity’ in RA. A ‘core 
set’ of measurements to assess disease activity for RA has been established (24). The 
core set consist of number of swollen joints (in a certain number of joints), number of 
tender joints (in a certain number of joints), patients assessment of joint pain, patients 
Core-set of efficacy endpoints for RA clinical trials 
Number of swollen joints 
Number of tender joints 
Patient’s assessment of joint pain 
Patient’s global assessment of disease activity 
Assessor’s global assessment of disease activity 
Acute phase response measure 
Functional assessment 
Radiological assessment (for studies of at least 1 year) 
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global assessment’ of disease activity (usually measured on Visual Analogue Scale 
(VAS)), assessor’s global assessment of disease activity (usually on a VAS), acute phase 
response measure (usually erythrocyte sedimentation rate and/or C-reactive protein), 
functional assessment (usually assessed using a self assessed questionnaire) and 
radiological assessment for periods exceeding 1 year (table 2). 
 
Table 3: ACR and EULAR response criteria 
EULAR criteria  
 Improvement in DAS28 from baseline: 
DAS28 at endpoint: > 1.2 > 0.6 and ≤ 1.2 ≤ 0.6 
≤ 3.2 Good   
> 3.2 and ≤ 5.1  Moderate  
> 5.1   Non 
ACR criteria 
20% improvement in 5 out of 7 core-set variables, first 2 required: 
Tender joint count 
Swollen joint count 
Acute phase reactant 
Patient’s pain 
Patient’s global assessment of disease activity 
Observer’s global assessment of disease activity 
Physical disability 
Differences EULAR and ACR criteria 
 EULAR ACR 
Developed in: Daily clinical practice Paper patients, trials 
Based on: Measurement error  
Level disease activity 
Rheumatologists’ impressions 
Minimized placebo response 
Components: Disease Activity Score Core-set variables 
Improvement: Change and level Change 
Categories: Three Two 
 
Specific criteria for improvement for use in clinical trials based on these core set 
measures have been established for use in clinical trials (30,31). Table 3 describes the 
two most frequently used response criteria. Those from the American College of 
Rheumatology (ACR) comprising of at least a 20% improvement in 5 out of 7 criteria 
with the joint counts being mandatory and the European League Against Rheumatism 
(EULAR) response criteria combining a change and an absolute level of attained 
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disease activity, using the DAS (28). Both are valid as outcome measures in RA clinical 
trials (30). 
 Apart from assessing the process of the disease (disease activity) it is also 
important to assess the outcome of the disease (joint damage: the result of the disease 
process over time). This is usually done by scoring this damage on x-rays of the joints 
of the hands and the feet. The most frequently used methods are the (modified) Sharp 
method and the Larsen-Dale method. The modified Sharp method counts erosions 
and joint space narrowing in joints of hands and feet and produces a score from 0 (no 
damage) to 448 (extensive damage) (32). The Larsen-Dale method (33) describes 5 
stages of RA in hands, wrists and feet joints according to reference films. The 
maximum score per joint is 5 and the maximum total score is 200. Both methods have 
been found to be valid and reproducible (32,33).  
 A key feature of RA is also the development of functional disability. Functional 
disability is usually measured with self-assessed measures, most frequently the Health 
Assessment Questionnaire (HAQ) (34). Although this instrument is also used in other 
populations it was developed specifically for patients with arthritis. It is very popular 
because it is a short questionnaire and easy to apply. The HAQ contains 20 items 
divided into 8 components namely walking, dressing and grooming, eating, reach, 
grip and outside activities. All items are scored on a scale of zero (no difficulties) to 
three (unable to do). The scores can be corrected for the usage of devices and help of 
other people. The maximum per category should be summated and averaged, 
resulting in a total score between zero (no disability) and three (severe disability). The 
HAQ has proved to be reliable, valid and sensitive to change (35,36). 
 
QUALITY OF LIFE ASSESSMENTS 
 
RA has a profound impact on the patients’ health related quality of life (HRQoL). 
Health related quality of life refers to the part of quality of life affected by a patient’s 
disease. Often self-assessed questionnaires are used to measure HRQol. With some of 
these questionnaires a so-called utility value can be calculated. A utility value is a value 
between 0 and 1 in which 0 represents dead and 1 represents ‘perfect health’. Utilities 
can also be derived by direct methods like the Time Trade Of (TTO) method and 
Standard Gamble Method. These direct measures are rarely used in RA since these are 
labor intensive and not feasible in the RA population. Using utilities, Quality Adjusted 
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Life Years (QALYs) can be calculated. This is calculated by multiplying the (life) time 
that is spent with the utility the time is spent in. The QALY is a frequently used 
outcome measure in cost-effective analysis.  
 
Figure 1: Quality of Life domains in rheumatoid arthritis patients versus the general 
population 
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Based on data from the article by Picavet et al (134) 
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In the absence of a cure for RA, improvement of quality of life is an important 
eventual goal of treatment. Figure 1 describes quality of life domains for an RA-
population as opposed to the general population using theSF36 and the EQ-5D. It can 
be seen that mainly the domains mobility or physical functioning, role limitations due 
to problems with physical functioning and pain are affected. Utility values of 
populations of RA-patients usually are between 0.53 and 0.75 and differ between the 
methods of assessing the utility value (37,38). 
HRQoL instruments, generic as well as disease specific, are nowadays more 
often used to measure therapeutic outcomes in clinical trials and daily clinical practice 
in RA. Although many quality of life instruments have been used in RA, the most 
commonly used instruments are the disease-specific Arthritis Impact Measurement 
Scale (AIMS) (39) and the Rheumatoid Arthritis Quality of Life questionnaire 
(RAQoL) (40), and the generic Medical Outcome Short-Form 36 (SF-36) (41), 
Nottingham Health Profile (NHP) (42), Health Utility Index (HUI) (43) and the 
EuroQol-5 dimensions (EQ-5D) (44). The HAQ is also frequently mentioned as an 
HRQol instrument, although it only measures one domain of quality of life, namely 
physical functioning. The HRQoL instruments will be reviewed in more detail in the 
following sections. 
 
Disease-specific instruments 
The AIMS contains items on physical and psychological functioning and pain. The 
original AIMS contains 45 items grouped into 9 scales. The AIMS has a high 
reliability, validity and sensitivity (39) but takes 15-20 minutes to administer (45). The 
AIMS2 is a revised and expanded version of the original AIMS and has a higher 
sensitivity than the original AIMS but takes even longer to administer (23 minutes) 
(46). 
The RAQoL is a relatively new quality of life instrument specially developed for 
patients with RA. It contains 30 items within 6 domains (mood, social life, hobbies, 
everyday tasks, personal and social relationships and physical contact) with a yes/no 
response format. The RAQoL has a high internal consistency and test-retest reliability 
and a good sensitivity to discriminate between groups with various disease activity 
(40).  
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Generic instruments, health profiles 
The NHP assesses perceived or subjective health by asking yes or no responses to 38 
statements in six different domains, namely energy level, emotional reaction, physical 
mobility, pain, social isolation and sleep. The questionnaire is sensitive to change in 
RA (47). 
The SF-36 is the most widely used generic quality of life instrument. It assesses 
8 domains including physical problems, role limitations due to physical problems, 
general health, vitality, pain, social function, general mental health and role 
limitations due to emotional problems. A total of 36 items are scored on a scale of zero 
(worst) to 100 (best) and for each domain a summary score can be calculated. The SF-
36 is an reliable, valid and sensitive instrument for RA (28,48,49).  
When comparing the NHP and the SF-36 it can be concluded that the SF-36 
has the best ability to discriminate between groups (50), but the NHP has a higher 
sensitivity to change (47) than the mental and physical component summary score of 
the SF-36. 
 
Generic instruments, utilities 
The EQ-5D is a generic instrument containing 5 dimensions including mobility, self-
care, usual activity, pain/discomfort and anxiety/depression with each items being 
divided into three levels (no, some and extreme problems). It is short and simply to 
administer. The EQ-5D is moderate responsiveness to change with small or medium 
standardized response means (35,47,51). Wolf and colleagues (52) concluded that the 
scoring properties and distributional aspects of the EQ-5D caused substantial 
problems when used in rheumatic diseases. They reported that the utility score did not 
reflect the visuals analogue scale quality of life score at low levels and the distribution 
of the utility score was not continuous.  
The HUI is a multi-attribute classification system referring to both the HUI 
mark 2 (HUI2) and HUI mark 3 (HUI3). The HUI3 comprises eight dimensions 
(vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain) with 
each domain having five to six response levels. The HUI2 does offer distinct, 
independent attributes including self-care, emotion that focus on worry/anxiety and 
fertility. For most applications the HUI3 should be specified as the measure for 
primary analysis (53). The HUI is proven to be a valid instrument in RA (36,37) but 
the sensitivity to change is small (47). 
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Recently an algorithm was developed for the SF-36 to derive utilities from this 
instrument (54). The new instrument, called the SF-6D, measures six domains of 
HRQoL: physical functioning, role limitations, social functioning, pain, mental health 
and vitality. The SF-6D shows a normal distribution and is sensitive to change in RA 
patients (35) but shows a floor effect (utility value of 0.30) (38). 
Several studies compared the three utility instruments for their validity 
reliability and sensitivity to change (36-38,47). The HUI was the least sensitive to 
change with a standardized response mean of 0.36 (47) but tended to have a higher 
test-retest reliability. The SF-6D was the most sensitive to change (SRM = 0,87) 
compared to the EQ-5D (35). The EQ-5D showed a binominal distribution with a gap 
between 0,3 and 0,5 and a ceiling effect, compared to a normal distribution of the HUI 
or SF-6D utility value (38). 
Conflicting results were found from the comparison of utility scores derived 
from the different instruments. Marra and colleagues (38) reported that the utilities 
score were statistically different, where Luo and colleagues (37) reported that they 
were not. Possible difference between the HUI or SF-6D utility score and the EQ-5D 
utility can be partly explained by a difference between valuation methods for deriving 
the utility algorithms (i.e. SG versus TTO). Therefore, it is unlikely that the utility 
values from these instruments, if used in calculating a QALY in economic evaluations, 
would result in comparable estimates. 
 
Which one to use? 
In general the disease specific instruments measure physical functioning and pain and 
are most responsive to changes in disease status. The generic instruments on the other 
hand measure also social and mental functioning but are less reliable and responsive 
to change. Guidelines for economic evaluation from many different countries 
recommend to measure utilities to calculate QALYs, which can easily be performed 
with the SF-6D, HUI or EQ-5D. Additionally, a disease specific instrument can 
provide detailed information on more disease specific aspects of quality of life. All 
instruments are not mutually exclusive and therefore a combination of generic and 
disease specific instruments is recommended. 
 
33 
 
COST ASSESSMENTS 
 
The impact of RA in terms of costs is substantial and often found to be more 
substantial than that of other chronic conditions including cardiovascular diseases 
and cancer (55). A recent systematic review of cost of illness studies in RA reported 
that the total direct and indirect costs ranged from US$ 1902 to 11503 US$ and from 
US$ 1082 to US$ 184222 per year, respectively (56). Inpatient costs (i.e. 
hospitalization) were found to represent the largest proportion of direct costs whereas 
the number of days absent from work was mostly responsible for the high indirect 
costs. All cost of illness studies reported wide ranges of total costs and costs were 
highly skewed. 
Variation of costs between subjects is of special interest. Disability (measured 
with the HAQ) or functional status were found to be strongly correlated with total 
costs (57-59). Next, disease duration influences direct costs in RA. Figure 2 show 
annual costs over disease duration. In the first two years costs were higher due to 
frequent consultations with health care workers. Thereafter, costs were lower until 5 
years after diagnosis, but increased steadily with disease duration, mainly due to 
hospitalization, devices and adaptation (60). Further, higher disease activity, pain, 
female gender, younger age and co-morbidities also predicted higher costs (58,61,62). 
 
Figure 2: Annual costs of RA of the disease course 
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Based on data from the article by Verstappen et al (135) 
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Cooper et al stated in his review that the variations in the annual costs of RA across 
studies can be attributed to a number of methodological problems and gave some 
guidelines for future cost of illness studies, which we would like to emphasize. Studies 
should: 1) report direct and indirect costs separately; 2) identify the different 
components of direct costs; 3) clearly state the data sources and unit process used to 
obtain the cost estimates. Further, variation in costs of illness studies in RA can result 
from differences in the healthcare system and in the perspective of the study (i.e. the 
societal perspective, health care perspective or patient perspective). To promote 
standardization of cost of illness studies, a list of cost domains to be evaluated was 
published recently (63). According to this list, all direct costs (e.g. outpatient and 
inpatient visits, visits to health care professional, medications, travel expenses, medical 
devices and home care) and costs related to loss of productivity should be included in 
cost of illness analyses.  
In economic studies in RA usually healthcare utilization and costs are 
measured using provider records or cost/utilization questionnaires or patient diaries. 
However the instruments used, differ considerably in items assessed, recall period, 
means of administration and response categories (64). 
 
COST-EFFECTIVENESS METHODOLOGY 
 
As just discussed, RA can have a high economic impact and patients are treated life-
long. Therefore investigating the cost-effectiveness of treatment (strategies) for RA is 
valuable. The goal of cost-effectiveness analysis is to establish whether the additional 
cost of a new intervention is justified given the additional benefits as compared to an 
alternative. The result of a cost-effectiveness analysis is usually expressed using a so-
called Incremental Cost Effectiveness Ratio (ICER). This measure is defined as the 
additional costs of an intervention compared to an alternative (the incremental costs) 
divided by the additional benefit of the intervention compared to the same alternative 
(the incremental effect). The threshold for which an (new) intervention is considered 
justified or cost-effective is somewhat arbitrary and still open to debate.  
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Table 4: Reference case for economic evaluations for rheumatoid arthritis 
Methodological Element Recommendation 
1. Study horizon Trial based analysis, minimum 1 year: model 
based analyses, minimum 5-10 years 
2. Duration of therapy Continuous 
3. Extrapolation beyond trial duration Report clinical trial data alone and 
extrapolate (model) using a synthesis of 
evidence from observational studies, trials, 
and other sources with sensitivity analysis 
(minimize use of expert opinion) 
4. Modeling beyond therapy No additional benefit or harm after therapy is 
stopped 
5. Synthesis of comparisons where head-to-
head trials do not exist 
Synthetic comparisons by using relative 
effects from controlled trials 
6. Clinical outcome measures Joint count, Pain by VAS, physical measure 
of function (e.g. HAQ). Measure of 
inflammation (CRP/ESR), HRQol. Toxicity 
(report adverse events with patients as the 
unit of analysis)  
7. Mortality Hazard rates for mortality from 
observational studies 
8. Valuation of health states (e.g. QALY) Patients’ values for clinical choices, general 
population’s values for health policy 
decisions 
9. Resource utilization Include all associated direct medical- and 
non-medical costs in the analysis, but report 
indirect costs (productivity losses) separately 
10. Discontinuation of therapy Use discontinuation rates from trials, 
adjusted using observational data 
11. Therapeutic sequence Include modeling of most commonly used 
therapeutic sequence with sensitivity analysis 
to consider other strategies 
12. Population risk stratification Include clear definition of underlying 
population including low and high risk 
groups 
VAS: visual analogue scale; HAQ: Health Assessment Questionnaire; HRQol: health related quality of 
life; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; QALY: quality adjusted life year. 
Based on the article of Gabriel et al (65) 
 
The conduct of cost-effectiveness analyses in RA has increased over the last years, 
prompted in part by new, highly effective but costly therapeutics for the treatment of  
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RA (20-23). Also the methodology for performing economic evaluations in RA has 
received more attention. In this regard the economics-working group of OMERACT 
(Outcome Measure in Rheumatoid Arthritis Clinical Trials) has done much work. 
This group tried to develop a RA specific reference case for economic evaluations in 
rheumatoid arthritis (65).Important methodological issues in economic evaluations in 
RA were discussed.  
The consensus included items such as: study horizon, duration of therapy, 
extrapolation beyond trial duration, modeling beyond therapy, synthesis of 
comparisons where head-to-head trials do not exist, clinical outcome measures, 
mortality, valuation of health states, resource utilization, discontinuation of therapy, 
therapeutic sequence, and population risk stratification. Table 4 summarized the 
reference case recommendations for economic evaluations in RA.  
 
MODELING 
 
Since for new treatments no long-term data on costs and effects (on quality of life) are 
available yet and patient with RA are treated for long periods (life-long), modeling 
long-term outcomes is unavoidable. Modeling involves mathematically combining 
(empirical) data from different sources (66). This approach can be used to overcome 
the problem of incomplete data and to extrapolate short-term endpoints to longer-
term outcomes. Since RA is a chronic disease, characterized by periods of high disease 
activity, alternating with periods of low disease activity, simple decision analysis does 
not suffice. A Markov model offers a methodology for dealing with recurring events 
and extended time horizons and therefore might be an appropriate model for RA (67).  
In a Markov model a hypothetical cohort of patients is simulated. The patients 
are classified in a finite number of mutually exclusive health states (Markov states), 
defined by the severity of the disease. These Markov states can be valued in terms of 
costs and effects. Development of the disease and the effectiveness of an intervention 
are represented as transitions from one Markov state to another in a defined time span 
(cycle length). These transitions occur with a certain probability (transition 
probabilities). According to these transition probabilities the simulation cohort is 
distributed over the Markov states, inducing expected costs and expected effects over a 
certain period (time horizon of the analysis) (66,67).  
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Although models inherently are a simplification of the real situation, care 
should be taken for the model to adequately represent the most important aspects of 
reality. Within Markov models transition probabilities can for instance be made 
dependant on time or on the history of the patient in the case of individual patients 
simulation (Monte Carlo simulation) to better represent the real life situation.  
Recently, Markov models have been used extensively in RA. The structures of 
these models differ from each other on several characteristics. First the measure used 
to define the Markov states differs. Some models use response to treatment defined as 
for instance ‘active disease’, or ‘% improved’ or ACR-response criteria (68,69). 
Another frequently used measure is the Health Assessment Questionnaire (HAQ) 
(57,70-74). Further, within some models separate Markov states for toxicity (69), 
progressive disease (68) and death (57,68,71,72) are used. Recently an RA model used 
the DAS to define Markov states (75). 
Markov states as defined in a model should make clinical sense, be mutually 
exclusive and capture the main differences between the treatment strategies (67,76). 
Markov states defined by response to treatment usually imply a relative measure of 
disease severity (a certain % improvement from baseline). Such a measure to define 
health states (over time) is probably justified for short-term analyses. In longer-time 
analyses absolute measures of disease severity should be used, because with relative 
measures, the baseline value has a large and continuing influence on the outcome later 
in time (77). Furthermore a model with cruder health states defined by for instance 
‘response yes/no’ might not be able to capture the differences between treatment 
strategies, due to residual confounding. 
The HAQ as well as the DAS comprise an absolute measure of clinical 
importance in RA. The HAQ is related to both process variables (disease activity) and 
outcome (i.e. joint damage), which might be an advantage as compared to for instance 
the DAS, especially with longer analysis horizons. The HAQ as well ass the DAS have 
a significant relation with costs and quality of life (57). However in early disease the 
HAQ is mostly related to disease activity and in later disease, the HAQ is also related 
to joint damage. Further the HAQ is defined by psychosocial factors (78,79). 
Therefore the relation of the HAQ with costs and utility might not be the same in 
different phases of the disease and in different populations and the utility and costs 
values for the Markov states defined by the HAQ should (also) be context/time 
specific. A clinically relevant division in the HAQ to define Markov states is less clear, 
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which is also apparent from the different definitions within the Markov models using 
the HAQ. For the DAS clear cut-of values for remission, low disease activity, moderate 
disease activity and high disease activity are present (80).  
Further the HAQ is not always uniform owing to variations in translation, 
adaptations and variations in its calculation, which is not always clear from the 
publications. This might indicate that absolute HAQ values are not interchangeable 
between different studies/populations (81). The above can present a problem when 
input data regarding HAQ-scores comes from different sources in modeling studies; 
using the DAS this is probably less of a problem.  
Another characteristic on which the Markov models differ is the cycle length. 
The definition of the cycle length is dependent on the definition of and changeability 
of the measure to define the Markov states. In principle the cycle length should be 
chosen to make clinical sense and with shorter cycle times treatment differences are 
estimated more precise (77). The appropriate cycle length depends on the clinical 
outcome measure used. Since 3 months is an often-used measurement interval in 
clinical studies and monitoring interval in clinical practice in RA, 3 months can be 
regarded a clinically relevant cycle time for disease activity based measures. This cycle 
time is probably also short enough to capture differences between treatments to be 
compared using the model. For other outcome measures this definition is less clear, 
and differences are present between the Markov models used.  
Finally Markov models differ on the total time-horizon of the model. Using 
disease activity measures as definition for the Markov states implies a relatively short 
time-horizon since disease activity describe disease state and not joint damage, but 
influences it (82). This problem might be overcome (partly) by using context/time 
specific cost and utility values, since an increase in damage does not influence costs 
and utility over short time periods. Further making the cost and utility values 
dependent on the previous course of the individual patient, thus incorporating the 
effect of increasing damage on cost/utility in the patient cohort might be an option. 
This adaptation is probably not needed with analyses horizons of 5 year and shorter 
when context specific valuation data are used. Longer or even life-long analyses might 
not be feasible anyway, due to data limitations especially with new treatments (77). 
With models using a time horizon beyond 5 years using an outcome measure not 
solely based on disease activity might be more appropriate. 
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For all models counts that the comparator used should reflect clinical practice 
(as in all economic evaluations), that the valuations of the Markov states should be 
context specific and assumptions (which usually need to be made in modeling studies) 
should be made conservative and extensive sensitivity analyses should always be 
performed (83,84). 
 
TREATMENT STRATEGIES 
 
We will now proceed with describing recent trends in treatment (strategies) and new 
treatments for active RA and describe the current literature on the effectiveness with 
special emphasis to the effects on quality of life and cost (-effectiveness) of these 
treatment (strategies). 
 
Present (optimal) therapy 
It has become increasingly clear that damage starts early in the disease (27,85). This 
has had an impact on the therapeutic strategies of patients with early RA: treat 
patients as soon as possible as aggressively as necessary in order to prevent joint 
damage. Nowadays DMARD treatment is being prescribed earlier than in the past, a 
shift in the use of DMARDs has occurred and more combination therapy is used 
(12,18,60,86-88). Further the new drugs leflunomide and the biologicals are more 
frequently used in RA. Currently the most used drugs in early RA are the DMARDs 
methotrexate and sulfasalazine and in more longstanding and severe disease 
leflunomide and the biologicals are used more often. In Europe patient are usually 
only treated with biologicals if patients have shown failure on 2 DMARDs of which 
one is methotrexate and have a moderate or high disease activity. A similar indication 
might apply for leflunomide (89,90). Another trend in the management of RA is to 
more closely monitor patients in daily clinical practice, using for instance the DAS28 
with guidelines to reach a defined low level of disease activity (91,92).  
 
Recent RCTs/ cohort studies of treatment (strategies) in RA 
 
Earlier vs late treatment 
It has increasingly become clear that earlier aggressive treatment has a benefit on 
disease activity as well as joint damage (93-96) and also improves outcome in terms of 
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loss of productivity (97), compared to late (less aggressive) treatment. It is sometimes 
even argued that early aggressive treatment has a continuing influence on outcome 
independent of follow-up treatment, however this is not shown unambiguously 
(95,98). 
 
Combination therapies 
The use of combination therapies has increased (12,87,99,100) and for some 
combinations superiority over the single components have been demonstrated, for 
instance the combination of methotrexate, sulfasalazine, hydroxychloroquine and 
prednisolone (95,101,102). Also the new biologicals are usually combined with a 
DMARD. The most studied combinations is with methotrexate and has shown to have 
a better outcome as compared to the single agents in these patients with usually long-
standing severe disease (88) 
 
Leflunomide trials 
Leflunomide is a reversible inhibitor of de novo pyrimidine synthesis, resulting in cell 
cycle arrest. Leflunomide has been used in daily clinical practice in RA since it has 
been shown to be effective (103,104). The percentage of patients with an ACR20 
response in RCTs is shown in table 5. Leflunomide also significantly improved 
functionality (103,105) and health related quality of life as measured with the SF36 
(106).Further, combination therapy with leflunomide and methotrexate provides 
statistically significant clinical benefit in patients with active arthritis who are 
receiving methotrexate therapy (107). 
 
Anti-TNFα-trials 
TNFα blocking agents have the ability to bind to the cytokine TNFα or the TNFα 
receptor, which is thought to play a role in the RA pathogenesis. The TNFα blocking 
agents, adalimumab, etanercept and infliximab, have been introduced recently. They 
have proved to be effective, as showed by a larger ACR20 response compared to 
placebo (table 5) in the treatment of both patients with late RA (DMARD failures) and 
early RA (DMARD naïve) 
 Further, all RCTs showed a significant improvement in functional disability 
(HAQ) compared to the placebo group. Etanercept (21) and infliximab (108) also 
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improved health related quality of life as measured with the SF36 and adalimumab 
showed a significant improvement on the HUI3 (109).  
 
Table 5: Recent clinical trials in RA 
Study N* FU-time 
(weeks) 
%ACR20 %ACR 
placebo 
TNFα blocking agents, DMARD failures     
Adalimumab (40 mg biweekly) + MTX†     
Weinblatt, 2003 (124) 67 24 67 15 
Furst, 2003 (125) 318 24 53 35 
Keystone, 2004 (126) 207 54 59 24 
     
Adalimumab (40 mg biweekly)     
Van de Putte, 2003 (127) 70 12 57 10 
Van de Putte, 2004 (128) 113 26 46 19 
     
Etanercept (25 mg twice per week) + MTX     
Weinblatt, 1999 (129) 59 12 71 34 
Lan, 2004 (130) 29 24 90 27 
     
Etanercept (25 mg twice per week)     
Moreland, 1997 (131) 44 13 75 14 
Moreland, 1999 (21) 78 26 59 11 
     
Infliximab 3 mg/ kg/ 8 weeks + MTX     
Maini, 2004 (108) 86 102 42 16 
     
TNFα blocking agents, DMARD naïve      
Etanercept (25 mg twice per week) +MTX     
Bathon, 2000 (132) 207 52 72 65 
Genovese, 2002 (123)  207 104 72 59 
     
Inflximab, 3 mg/ kg/ 8 weeks + MTX     
St Clair, 2004 (133) 359 54 62.4 53.6 
     
Leflunomide     
Strand, 1999 (103) 182 52 52 26 
Smolen, 1999 (104) 78 52 67 NA 
Kremer, 2002 (107)  
(Lef+MTX vs Lef +placebo) 
130 24 46 20 
* Number of patients in treatment group; † MTX = methotrexate; NA = not applicable 
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Monitoring Trials 
In several studies closely monitoring patients with tight control of disease activity 
seems to have a beneficial effect on disease activity of patients (91,92). It has also been 
shown in the TICORA (tight control for rheumatoid arthritis) study to improve the 
progression of joint damage, physical function (HAQ-DI) and quality of life (91). 
Table 5 summarizes the clinical trials with the new drugs for RA and monitoring. 
 
Costs-effectiveness of recent treatment (strategies) 
 
For some of the above-mentioned recent treatment (strategies) also cost-effectiveness 
analyses have been performed. Concerning early aggressive treatment a cost-
effectiveness analysis based on the COBRA study was performed. It was concluded 
that combination therapy with step-down prednisolone, methotrexate and 
sulfasalazine was not more expensive (direct as well as indirect medical costs) as 
opposed to sulfasalazine monotherapy and utility scores also favored combined 
treatment (110,111). Since traditional DMARD therapy is not very expensive, earlier 
initiation of DMARD therapy and combination therapy, if effective, are probably also 
cost-effective, although we are not aware of any formal cost-effectiveness analysis. 
For leflunomide and the biologicals several cost effectiveness analyses have 
been performed with widely varying outcomes, probably mostly due to differences in 
methodology. Choi et al (112) compared treatment options for methotrexate-resistant 
RA. In this study a reference analysis of methotrexate therapy for methotrexate-naive 
RA, compared with no treatment, costing $1.100/ACR 20% response, was used to 
compare cost-effectiveness ratios. The authors concluded that triple therapy 
(hydroxychloroquine, sulfasalazine and methotrexate) is probably cost-effective in 
this patient group since the costs were only 1.3 times more per ACR 20% response 
compared to the reference analysis. Etanercept in combination with methotrexate had 
a high cost-effectiveness ratio of $42.600/ACR20% response over 6 months (38 times 
more compared with the reference case). The other treatment options continuing 
methotrexate, etanercept monotherapy, cyclosporine plus methotrexate and no 
second-line agent were dominated. This study had a time horizon of only 6 months, 
and did not use non-disease-specific outcome measures like utility for comparison 
with cost-effectiveness studies in other diseases.  
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Wong et al (72) estimated the cost-effectiveness of 54 weeks of infliximab as 
compared to methotrexate treatment in patients that had active disease despite 
treatment with methotrexate. They projected the 54-week results from the ATTRACT 
trial into lifetime economic and clinical outcomes using a Markov model with Markov 
states defined by the health assessment questionnaire. Since the effectiveness of 
infliximab beyond the 54 weeks was not available, they assumed that infliximab would 
be discontinued and that patients would start methotrexate treatment. This 
assumption is probably not valid and results in an underestimation of the incremental 
cost-effectiveness ratio. Furthermore infliximab treatment was compared with 
methotrexate treatment in a group of patients that did not respond well to treatment; 
this is probably not the best available alternative and/or the usual treatment for these 
patients. The authors concluded that 54 weeks of infliximab treatment should be cost-
effective at $9100/QALY.  
Recently Brennan et al compared a DMARD sequence with etanercept as a 
third line to a DMARD sequence excluding etanercept in RA patients that failed two 
DMARDs (113). They calculated lifetime economic and quality of life outcomes using 
a decision model that focused on the progression of HAQ disability and simulates 
individual patients histories according to the chance of responding to treatment (ACR 
20%), adverse event and death. They found a DMARD sequence including etanercept 
(as a third-line DMARD) to be cost-effective with an ICER of £16.330 per QALY 
($31.188/QALY).  
Two studies (114,115) investigated the costs of RA care in patients who started 
treatment with leflunomide as compared with etanercept (and infliximab (115)). 
These studies concluded that RA-care costs in the leflunomide group were lower 
($7722.01 +/- $5285.20 versus $3301.84 +/- $4054.75 over 6 months). This difference 
was primarily related to differences in RA-related pharmacy charges ($5877.78 
$2237.68 versus $1877.23 +/- $1258.05; P < .0001 (114) and $9618 versus $16,534 and 
$20,263 for etanercept and infliximab, respectively), primarily as a result of lower 
medication costs (115)). The treatments were not compared on effectiveness, however, 
and one of the studies was retrospective (114). The costs were based on databases 
containing patient-level medical and pharmaceutical claims. The exact patient 
population for this study was unclear. One study compared a DMARD sequence 
including leflunomide treatment with a DMARD sequence without leflunomide in 
patients with RA severe enough to require treatment with methotrexate. They used a 
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decision model in which patients could respond to therapy or not (ACR 20%), 
continue therapy, stop therapy and experience adverse events. The time horizon of the 
analyses was 5 years. It was concluded that adding leflunomide as a new options to a 
conventional sequence of DMARDs was reasonably cost effective with a ICER of 
$54.229 or $71.988 per QALY gained, depending on the method of calculating QALYs 
(116).  
Barton et al compared the cost-effectiveness of a DMARD-strategy including 
etanercept or infliximab (as a third line DMARD) compared to a DMARD sequence 
without these TNFα blocking agents and found the ICER to be between £50.442 and 
£68.591 per QALY. The Birmingham Rheumatoid arthritis model (BRAM) a decision 
model an individual sample model was used. Further the TNFα blocking agents were 
compared and etanercept was found to have an ICER of about £28.096 (26.377-
30.054) per QALY as compared to infliximab (73). Using the same model Clark et al 
studied DMARD sequences with and without anakinra at different points in the 
DMARD sequence. Incremental Cost-effectiveness ratio’s were found to be between 
£106.000 and £604.000/QALY (74).  
Welsing et al used a Markov model, with a cycle length of 3 months and 
Markov states defined by the Disease Activity Score to compare several treatment 
strategies including leflunomide and TNFα blocking treatment in patients that failed 
two DMARDs of which one was methotrexate and had a high disease activity. They 
found that the strategies including TNFα blocking treatment and leflunomide were 
more effective, than strategies with only traditional DMARDs. A strategy that started 
with leflunomide and in case of non-response started TNFα blocking treatment had 
an ICER of 163.556 EURO/QALY ($211.321/QALY) as compared to leflunomide 
treatment alone, and was the most cost-effective strategy of the strategies with TNFα 
blocking agents (75). 
Concerning a treatment strategy of monitoring with tight control of disease 
activity the cost analysis of the TICORA study found that the costs were lower in the 
intensive group than in the routine group but did not differ significantly for total 
hospital costs per patient or total community costs per patients. Although outpatient 
and prescribing costs were higher in the intensive treatment arm, higher inpatient 
costs in the routine group offset these effects. 
Some ICERs seemed rather high, but the authors stated that the strategy of 
interest was cost-effective. Although no clear statement can be found on a cost-
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effectiveness threshold above which health technologies are automatically rejected and 
below which technologies are accepted, Dutch health authorities have accepted 
technologies with cost-effectiveness ratios below 50.000 euro ($64.602). (117). The 
Australian reimbursement authorities have been unlikely to recommend a drug if the 
cost-effectiveness ratio exceeded AU $76.000 ($59.417) per life year saved and unlikely 
to reject it if less than $42.000 ($32.836) per life-year saved (118) An upper threshold 
of about £30 000 ($57.296)per quality-adjusted life-year seems to have emerged at 
NICE (119). Nevertheless, uncertainty of cost-effectiveness results and the burden of 
disease explains reimbursement decisions better than cost effectiveness alone (120) 
 
Factors influencing choice of treatment 
 
It appeared from a survey of British rheumatologists that poor prognostic factors led 
to a preference for earlier methotrexate, anti-TNFα agents and combination therapy 
(121). Also side effects and co morbid conditions affected DMARD choice. 
Rheumatologists were partly influenced by patient’s preferences and not by patients 
occupation and drug costs.  
 In a study of patient preferences for treatment in RA, older patients with RA, 
when asked to consider trade-offs between specific risk and benefits, preferred 
etanercept over methotrexate, gold or leflunomide (122). This is explained by older 
patient’s risk aversion for drug toxicity. From all responders, 80% to 95% preferred 
etanercept over the other above mentioned treatment options, despite a maximum co-
payment of $30.00 per month.  
 
EXPERT OPINION 
 
The treatment strategy of RA has changed dramatically over the last decades. Patients 
are treated earlier and more aggressive and new DMARD and the biologicals have 
been introduced in daily clinical practice. Further closely monitoring to keep disease 
activity at a low stable level is being advocated. Rheumatoid arthritis has an extensive 
impact on quality of life and the costs for society of this disease are high. Therefore 
treating these patients adequately has the potential to be cost saving. However these 
cost-offsets might be found later in the disease for instance by preventing orthopedic 
surgery. Since RA is chronic disease with a life long treatment the long-term 
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assessment of cost-effectiveness usually implies modeling. Although there are 
developments in the direction of common standards for these kind of analysis, much 
has still to be achieved resulting in many different model strategies with ditto 
outcomes. This is also because of a large lack of data and head-to head comparisons of 
different treatment (strategies). 
Some conclusions can be made: Since traditional DMARD treatment is not 
expensive, probably the strategy of early aggressive treatment is cost-effective since 
these strategies do not seem to result in extra toxicity and are usually found to be 
effective. Also closely monitoring patients if effective is probably cost-effective. The 
place of the new drugs for rheumatoid arthritis remains somewhat controversial, since 
cost-effectiveness analyses have varying results. However these agents are being 
actively used in current daily clinical practice and some advocate their use earlier in 
the disease (123). 
 
5-YEAR VIEW 
 
For the coming years more data will become available on the use of the new DMARDs 
and biologicals on costs and quality of life through the (biologics) registries 
throughout the world. This will give more insight into the longer-term effects of these 
treatments. This will probably also make it possible to (partly) validate existing 
modeling strategies. This will hopefully increase the modeling methodology in RA and 
will encourage common standards. 
New clinical trials will emerge in which the biologicals will be used in patients 
in earlier disease. This will show if earlier treatment with these agents has additive 
benefit compared to using these agents as third of fourth line treatment. Also the use 
of early and aggressive treatment and the influence later in the disease course will 
probably be studies more often, since long lasting (inception) cohorts are able to 
compare treatments strategies over time. 
Monitoring and guidelines will probably be used more often in analogy with 
other diseases such as high blood pressure and diabetes and more information 
regarding efficacy of new treatments in sub-groups of patients will be available and 
influence daily clinical practice.  
Finally, many new biologicals, like for instance CTLA4-IG (abatacept) and 
Rituxan (rituximab) will be introduced for the treatment of RA and will be studied for 
47 
 
their cost-effectiveness in the treatment of RA. And this will also determine their place 
within the treatment of this disease (as compared to the existing biologicals). 
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ABSTRACT 
 
Background: Randomized controlled trials (RCTs) evaluating the efficacy of 
antagonists to TNFα showed high response percentages in the groups treated with 
active drugs.  
Objective: To compare the efficacy of anti-TNFα treatments for Rheumatoid Arthritis 
(RA) patients in RCTs and in daily clinical practice, with an emphasis on the efficacy 
for patients eligible and non-eligible for RCTs of anti-TNFα treatments.  
Methods: First, randomized placebo-controlled trials written in English for 
etanercept, infliximab and adalimumab for patients with RA were selected by a 
systematic review. Second, the DREAM (Dutch Rheumatoid Arthritis Monitoring) 
register with patients starting for the first time on one of the TNFα blocking agents 
was used. Patient characteristics, doses of medication and co-medication as well as the 
ACR20 response percentages were compared between RCTs and DREAM data, 
stratified for trial eligibility. 
Results: In ten of eleven comparisons, the ACR20 response percentages were lower in 
daily clinical practice than in the RCT active drug group, which was significant in five 
of eleven comparisons. Only 34% to 79% of DREAM patients fulfilled the selection 
criteria for disease activity in the several RCTs. DREAM patients eligible for RCTs had 
higher response percentages then ineligible DREAM patients. ACR20 response 
percentages of eligible DREAM patients were comparable with the ACR20 response 
percentages of the RCT active drug group in ten of eleven comparisons. 
Conclusion: The efficacy of TNFα blocking agents in RCTs exceeded the efficacy of 
these drugs in clinical practice. However, in clinical practice more patients with lower 
disease activity were treated with TNFα blocking agents compared with those treated 
in RCTs. For daily practice patients who were eligible for RCTs, responses were more 
similar to responses reached in RCTs.  
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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a chronic, progressive inflammatory disease with the 
potential to cause cartilage destruction and bone erosions (1). Up to present the 
etiology of RA is unknown. Pro-inflammatory cytokines such as tumor necrosis 
factor-α (TNFα) have been suggested to play a central role in the pathogenesis of the 
disease (2). Inhibition of TNFα has been shown to reduce disease activity and to delay 
the process of progressive joint damage (3-5). Presently, three different anti-TNFα 
agents are available for patients with RA: etanercept (Enbrel®), infliximab (Remicade®) 
and adalimumab (Humira®). 
Randomized controlled trials (RCT) on anti-TNFα show high response 
percentages. It is suggested that comparable efficacy is hardly ever achieved in daily 
clinical practice (6). Difference in efficacy between RCTs and clinical practice might 
be explained by: patient selection; wash-out period before inclusion, which artificially 
increases the disease activity; differences in the doses; co-medication; occurrence of 
co-morbidity; and adherence.  
In the present study we compared the efficacy of anti-TNFα drugs in RA from 
RCTs with their efficacy in the Dutch Rheumatoid Arthritis Monitoring (DREAM) 
cohort on anti-TNFα (daily clinical practice).  
 
METHODS 
 
We performed a systematic review of RCTs of anti-TNFα agents in RA with an 
emphasis on efficacy parameters as well as data on dose, co-medication and patients’ 
characteristics. The RCT data were compared with the data from the DREAM cohort, 
reflecting daily clinical practice.  
 
Systematic review 
Identification of studies 
RCTs (phase III studies) were identified from the Medline database (published before 
the end of 2005) by using the search strategy for randomized controlled trials 
described in “Systematic reviews in health care” (7). The search strategy was combined 
with the following terms to identify relevant studies for our purpose: rheumatoid 
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arthritis and ((etanercept or Enbrel or infliximab or Remicade or adalimumab or 
Humira) or tumor necrosis factor or TNF) 
Based on title and abstract, all studies that compared etanercept, infliximab or 
adalimumab with a placebo in the treatment of rheumatoid arthritis were included, 
regardless of the concomitant use of methotrexate (MTX). We focused on studies that 
evaluated treatment groups with a comparable dose and frequency as labeled in the 
Netherlands: (40 mg adalimumab once/2 weeks, 25 mg etanercept twice weekly and 
3mg/kg infliximab per 8 weeks). Only articles written in English were included. Final 
inclusion and exclusion decisions were made after the articles had been examined. If 
more than one article from the same study was found, the first article published was 
included.  
 
Data extraction 
The included trials were evaluated with respect to patient characteristics, dosage of 
anti-TNFα, MTX and co-medication and efficacy parameters using predefined data 
entry forms. Different total joint counts were reported in the articles and the daily 
clinical practice database. For comparison of baseline characteristics, reported joint 
counts were converted from number of joints into percentage of joints. The primary 
efficacy outcome was the percentage patients with an ACR20 response in the active 
drug group and in the placebo group.  
 
Daily clinical practice data 
In April 2003, a register was started to prospectively monitor and evaluate the use of 
anti-TNFα in patients with RA in 11 hospitals in the Netherlands, the Dutch 
Rheumatoid Arthritis Monitoring (DREAM) study on anti-TNFα. In the Netherlands, 
patients are allowed to start with any anti-TNFα therapy if they meet the following 
criteria: 1) Diagnosis of RA (according to ACR criteria, 1987 (8)); 2) Disease activity 
score (DAS28) > 3.2 (9); 3) Previous treatment with at least two other anti-rheumatics 
including MTX at an optimal dose (maximum dose of 25 mg/day) or intolerance for 
MTX. All RA patients in the 11 hospitals starting on anti-TNFα for the first time were 
included in the DREAM register. Patients were treated at the discretion of the 
attending physician. 
Independent trained research nurses assessed patients every three months and 
collected data on patients’ demographics, disease activity, treatment, dosages and 
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adverse events. Disease activity was measured using ‘core set’ measures: 28 joint count 
for tender and swollen joints, erythrocyte sedimentation rate (ESR), CRP level, the 
HAQ and visual analogue scales (VAS) for general health, disease activity and pain. 
Additionally, information on patient characteristics and therapeutic setting was 
available in this register. 
 
Analysis 
To compare the patient characteristics, the following variables were analyzed: dosage, 
disease duration, age, gender, rheumatoid factor, percentages of tender and swollen 
joints, number of prior DMARDs, concomitant DMARD, corticosteroid and NSAID 
use. In order to obtain an indication of the relevance of differences in baseline values 
between RCT and DREAM, mean values and SE’s of the mean were calculated on the 
basis of standard deviations as presented in the articles. Because the joint counts were 
converted from number of positive joints into percentage of positive joints, SE’s of the 
percentage of joints affected were calculated as the SE of a proportion. 
Because the physician global assessment was not present in the DREAM 
register modified ACR20 response percentage were calculated as primary outcome. 
Modifications were done in two ways. First ACR20 response was calculated as a 20% 
improvement in four out of six parameters giving an overestimation of the percentage 
of patients with a response. Second an underestimation was calculated as a 20% 
improvement in five out of six parameters. Both ACR20 response percentages are 
presented in this paper. All efficacy data were analyzed as intention-to-treat analyses 
with a non-responder imputation.  
Differences in ACR20 response percentages between the RCTs and the daily 
clinical practice data were statistically tested for every single RCT. In order to correct 
for multiple testing of the same hypothesis, we adjusted the significance level by the 
Bonferroni correction. We hypothesized that the response in daily clinical practice 
will be less impressive than in the RCTs. Therefore focus will be on the most 
conservative comparison of the overestimation of ACR20 response with the RCT 
active drug response. 
The percentage of patients in the daily clinical practice eligible for the RCTs on 
basis of the RA activity was calculated for each study. Furthermore, groups of eligible 
and ineligible patients were compared to the RCT active drug group with regard to the 
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overestimation of the percentage of patients with an ACR20 response. All analyses 
were performed using SPSS 12®. 
 
RESULTS 
 
Systematic review 
The search strategy yielded 492 records. On the basis of title and abstract, a total of 27 
potentially relevant papers were selected and retrieved to obtain more detailed 
information. Of these 27 papers, a further fifteen were excluded: thirteen phase I or 
phase II studies and two studies of early RA patients. Of the remaining twelve papers, 
five concerned etanercept (10-14), two concerned infliximab (15,16) and five 
concerned adalimumab (17-21). One study (15,19) was excluded from the comparison 
of efficacy because only the response according to the Paulus criteria was presented in 
the article. All studies but one (Furst et al. (19)) used a wash-out period of 4 weeks for 
all DMARDs except MTX in the add on studies. The follow-up time in the selected 
studies ranged from 12 to 30 weeks. 
 
Table 1: Patient characteristics in RCTs and DREAM study  
Study N Dis dur (months) Age (yrs) % female % RF+ 
Adalimumab + MTX      
• Weinblatt, 2003 67 12.2 (1.4) 57.2 (1.4) 74.6  
• Furst, 2003 318 9.3 (0.49) 55 (0.72) 79.6 63.4 
• Keystone, 2004 207 11.0 (0.64) 56.1 (0.94) 76.3 81.6 
DREAM study 186 9.6 (0.63) 55.4 (0.93) 66.9 80.1 
Adalimumab mono      
• Van de Putte, 2003 70 10.0 (0.84) 52.6 (1.4) 87 91 
• Van de Putte, 2004 113 10.6 (0.65) 52.7 (1.3) 79.6 79.6 
DREAM study 31 13.7 (1.9) 56.0 (2.1) 76.3 81.6 
Etanercept + MTX      
• Weinblatt, 1999 59 13 48 90 84 
• Lan, 2004 29  47.6 83  
DREAM study 171 9.0 (0.77) 55.0 (1.1) 69.1 74.7 
Etanercept mono      
• Moreland, 1997 44 80% > 5 yr 52 82  
• Moreland, 1999 78 11 53 74 79 
• Keystone, 2004 153 8.2 52 79 64 
DREAM study 45 9.4 (1.0) 55.7 (1.8) 76.3 76.3 
Infliximab + MTX      
• Maini, 1998 15 12.1 (2.3) 58.9 (2.6) 67 66.7 
• Attract, 99-04 # 86 8.4 (0.7-45) 56 (25-74) 70 72 
DREAM study 103 9.6 (0.9) 58.3 (1.2) 67.9 76.4 
Data presented as means and standard errors where possible. Dis dur = Disease duration. 
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DREAM study 
By December 2005, 546 patients had been included in the register. Five treatment 
groups were observed: infliximab with MTX (N=103), etanercept with MTX (N=171) 
and without MTX (N=45), adalimumab with MTX (N=186) and without MTX 
(N=31). For the infliximab patients the mean time of follow-up was 20 months; for all 
other patients it was 13 months. Baseline characteristics are presented in Table 1.  
The percentage of patients stopping anti-TNFα treatment within 6 months 
(maximal follow-up time of the included articles) differed for the several treatment 
approaches: 6.8% stopped in the adalimumab with MTX group, 41.9% in the 
adalimumab mono-therapy group, 11.4% in the etanercept with MTX group, 26.7% in 
the etanercept monotherapy group and 16.5% in the infliximab with MTX group. 
However, the occurrence of reasons for stopping, adverse events as well as lack of 
effectiveness, was comparable in all groups. 
 
Table 2: ACR core set baseline values in RCTs and DREAM study 
Study N SJ* TJ* 
CRP 
(mg/ml) 
HAQ 
VAS pain 
0-100 
VAS DAS 
0-100 
Adalimumab + MTX        
• Weinblatt, 2003 67 26.2 (5.4) 41.2 (5.9) 21 (2.2) 1.55 (0.07) 53.0 (2.7) 56.9 (2.6) 
• Furst, 2003 318 31.7 (5.7) 40.1 (5.9) 15 (1.1) 1.37 (0.03) 55.1 (1.3) 53.9 (1.3) 
• Keystone, 2004 207 29.2 (5.6) 40.1 (5.9) 18 (1.6) 1.45 (0.04) 55.9 (1.4) 52.7 (1.5) 
DREAM study 186 29.5 (8.6) 32.3 (8.8) 21 (2.0) 1.3 (0.05) 60.2 (1.8) 60.6 (1.6) 
Adalimumab mono        
• Van de Putte, 2003 70 28.3 (5.5) 45.6 (6.0) 56 (4.7) 1.74 (0.8) 73.4 (2.3) 64.8 (2.2) 
• Van de Putte, 2004 113 31.1 (5.7) 50.0 (6.0) 53 (3.5) 1.83 (0.06) 70.1 (1.9) 72.5 (1.8) 
DREAM study 31 29.3 (8.6) 30.6 (8.7) 26 (4.9) 1.5 (0.12) 57.3 (3.9) 55.2 (3.5) 
Etanercept + MTX        
• Weinblatt, 1999 59 29.4 39.4 22 1.5 50.0 60.0 
• Lan, 2004 29 47.0 (9.4) 50.0 (9.4) 17 0.99 55.2 66.2 
DREAM study 171 36.1 (9.1) 32.3 (8.8) 19 (1.7) 1.3 (0.06) 60.3 (1.9) 59.9 (1.8) 
Etanercept mono        
• Moreland, 1997 44 35.3 (5.8) 42.3 (5.9) 36 1.35 63 65 
• Moreland, 1999 78 36.8 (5.8) 46.5 (5.9) 47 1.6 67 70 
• Keystone, 2004 153 28.2 (5.4) 41.1 (5.6) 19 (5.0) 1.4 53 60 
DREAM study 45 36.3 (9.1) 35.7 (9.1) 23 (3.3) 1.5 (0.09) 67.4 (3.9) 68.1 (3.7) 
Infliximab + MTX        
• Maini, 1998 15 24.2 30.9 42 2.0 60 65 
• Attract, 99-04 # 86 28.8 (20-46) 47.1 (24-68) 31 (13-53) 1.8 (1.4-2.3) 70 (56-81) 66 (49-78) 
DREAM study 103 31.3 (8.8) 33.9 (8.9) 27 (4.0) 1.4 (0.08) 58.3 (2.6) 54.7 (2.6) 
All data are presented as means and standard errors; * Mean numbers of swollen and tender joints 
were converted to percentage of swollen and tender joint of the total number of joints counted; # 
Median values and ranges (age and disease duration) or interquartile ranges (SJ, TJ and CRP) 
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Only minor differences in patient characteristics and ACR core set baseline values 
between the RCTs and DREAM study were observed (Table 1 and Table 2). CRP 
levels, tender joint counts, HAQ, VAS pain and VAS global values were significant 
lower in de DREAM data compared to both Van de Putte trials.  
Anti-TNFα and MTX dosage as well as the use of NSAIDs were comparable. 
Twentynine-54% of DREAM patients used corticosteroids, where the corticosteroid 
use in RCT ranged from 44% to 69%. In RCTs, the prednisone dose was limited to a 
stable dose of maximal 10 mg/day. In the DREAM patients using corticosteroids, the 
baseline prednisone dosage was approximately 10 mg/day but 40% of these patients 
stopped using it after starting anti-TNFα. 
 
Figure 1: The efficacy of anti-TNFα in the active drug group (Active) and the placebo 
group as the percentages of patients with an ACR20 response compared to the over- 
and underestimation of the ACR20 response in daily clinical practice  
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Abbreviations for anti-TNFα agents: AD is adalimumab, ET is etanercept and IN is infliximab 
 
Figure 1 presents a graphical display of the effects of anti-TNFα on the ACR20 
response in DREAM patients, as well as in the RCT active drug group and in the 
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placebo group. The ACR20 response percentages are generally lower in daily clinical 
practice than in the RCT active drug group. This difference is significant in five of 
eleven comparisons with the overestimation and in nine of eleven comparisons with 
the underestimation (Table 3). The absolute difference between the RCT active drug 
group and daily clinical practice ranged varied between 2% and -44% for the 
overestimation and between -11% and -56% for the underestimation of ACR20 
response percentages. For Adalimumab the difference in responses was smallest and 
for etanercept the differences were largest. 
Although our results presented in table 1 indicated that the baseline values and 
patient characteristics were comparable between the RCT and the DREAM 
population, Table 4 shows that only 34% to 79% of DREAM patients fulfilled the 
inclusion criteria for baseline disease activity in the RCTs. 
 
Table 3: The efficacy as the percentage of patients with an ACR20 response  of anti-
TNFα in the active drug group (Active) and daily clinical practice (DREAM)  
   Overestimation Underestimation 
Study Active Follow time 
(weeks) 
DREAM Δ p-value DREAM Δ p-value 
Adalimumab + MTX         
• Weinblatt, 2003 67,2 24 54,9 -12,3 0,04411 41,8 -25,4 0,00026 
• Furst, 2003 52,8 24 54,9 2,1 0,66326 41,8 -11 0,01383 
• Keystone, 2004 63,3 24 54,9 -8,4 0,05409 41,8 -21,5 0,00003 
Adalimumab mono         
• Van de Putte, 2003 57 12 29,0 -28,0 0,00470 22,6 -34,4 0,00069 
• Van de Putte, 2004 46 24 40,0 -6,0 0,29261 32,0 -14,0 0,10066 
Etanercept + MTX         
• Weinblatt, 1999 71 24 44,5 -26,5 0,00029 31,5 -39,5 0,00000 
• Lan, 2004 90 12 45,7 -44,3 0,00001 34,4 -55,6 0,00000 
Etanercept mono         
• Moreland, 1997 75 12 40,5 -34,5 0,00059 23,8 -51,2 0,00000 
• Moreland, 1999 59 24 31,6 -27,4 0,00280 26,3 -32,7 0,00047 
• Keystone, 2004 63 16 40,5 -22,5 0,00442 23,8 -39,2 0,00000 
Infliximab + MTX #         
• Attract, 99-04  50 30 32,2 -17,8 0,01665 27,1 -22,9 0,00291 
# Maini et al presented only Paulus criteria in their articles. Bonferroni correction resulted in a P-
value < 0.0045 (0.05/11) considered significant 
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Table 4: Percentage of DREAM patients eligible for the RCTs on the basis of disease 
activity 
Study Criteria active RA in RCT eligible DREAM patients (%) 
Adalimumab + MTX   
• Weinblatt, 2003 ≥ 9(/68) TJ, ≥ 6(/66) SJ 146/186 (78.5%) 
• Furst, 2003 ≥ 6(/68) TJ, ≥ 6(/66) SJ 138/186 (74.2% 
• Keystone, 2004 ≥ 9(/68) TJ, ≥ 6(/66) SJ, CRP > 1 mg/dl, RF+ 61/186 (32.8%) 
Adalimumab mono   
• Van de Putte, 2003 ≥ 12(/68) TJ, ≥ 10(/66), ESR≥28 or CRP ≥ 2 mg/dl 9/31 (29.0%) 
• Van de Putte, 2004 ≥ 12(/68) TJ, ≥ 10(/66), ESR≥28 or CRP ≥ 2 mg/dl 9/31 (29.0%) 
Etanercept + MTX   
• Weinblatt, 1999 ≥ 6(/71) TJ, ≥ 6(/68) SJ 126/171 (73.7%) 
• Lan, 2004 ≥ 6(/28) TJ, ≥ 6(/28) SJ 87/171 (50.9) 
Etanercept mono   
• Moreland, 1997 ≥ 12(/71) TJ, ≥ 10(/68) SJ, ESR ≥28 or CRP > 2 mg/dl 18/45 (40.0%) 
• Moreland, 1999 ≥ 12(/71) TJ, ≥ 10(/68) SJ, ESR ≥28 or CRP > 2 mg/dl 18/45 (40.0%) 
• Keystone, 2004 ≥ 6(/71) TJ, ≥ 6(/68) SJ 36/45 (80.0%) 
Infliximab + MTX   
• Maini, 1998  
≥ 6(/68) TJ and at least 2 of the following ≥ 6(/66) SJ, 
ESR>28, CRP > 1.5 mg/dl 
49/103 (47.6%) 
• Attract, 99-04 ≥ 6(/68) TJ, ≥ 6(/66) SJ, ESR>28 or CRP > 2 mg/dl 44/103 (42.7%) 
 
Figure 2: The efficacy of anti-TNFα in the active drug group and the placebo group as 
the percentages of patients with an ACR20 response compared to the overestimation 
of the ACR20 response in eligible and ineligible daily clinical practice patients.  
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Abbreviations for anti-TNFα agents: AD is adalimumab, ET is etanercept and IN is infliximab 
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Figure 2 presents a graphical display of the effects of anti-TNFα on the overestimation 
of the ACR20 response in DREAM patients eligible and ineligible for the RCTs as well 
as in the RCT active drug group and in the placebo group. The number of eligible or 
ineligible patients is very small in some comparisons (see Table 4), giving rise to large 
standard errors. The ACR20 response percentages in patients eligible for the RCTs 
generally were still lower than the RCT responses (Figure 2). The difference between 
the RCTs and eligible DREAM patients was statistically significant in 1 of eleven 
comparisons (Table 5). The absolute difference between the RCT active drug group 
and eligible DREAM patients ranged from 14.7 to –35 %. The absolute difference 
between the RCT active drug group and ineligible DREAM patients ranged from –
9.4% to -54.8% and was significant lower in six of eleven comparisons. 
DREAM patients who were eligible for the RCTs had higher response rates 
than ineligible patients. The absolute difference between the eligible and ineligible 
patients ranged from –9.6% to 44.2% in favor of the eligible patients but was 
significant higher in two comparisons.  
 
Table 5: The efficacy as the over-estimated percentage of patients with an ACR20 
response of anti-TNFα in the active drug group (Active) and the DREAM patients, 
eligible and ineligible for the RCTs  
  Eligible DREAM patients Ineligible DREAM patients 
Study Active N ACR20 Δ p-value* N ACR20 Δ p-value* 
Adalimumab + MTX          
• Weinblatt, 2003 67,2 115 67.8 0.6 0.5332 38 31.6 • -35.6 0.0002 
• Furst, 2003 52,8 123 67,5 14.7 0.9971 30 23.3 • -29.5 0.0011 
• Keystone, 2004 63,3 51 68.6 5.3 0.7605 102 53.9 -9.4 0.0562 
Adalimumab mono          
• Van de Putte, 2003 57 9 50.0 -7.0 0.3527 17 35.3 -21.7 0.0540 
• Van de Putte, 2004 46 8 22.2 -23.8 0.0833 22 31.8 -14.2 0.1096 
Etanercept + MTX          
• Weinblatt, 1999 71 109 54.1 -16.9 0.0164 37 32.4 -38.6 0.0001 
• Lan, 2004 90 80 55.0 -35.0 0.0004 71 35.2 -54.8 0.0000 
Etanercept mono          
• Moreland, 1997 75 14 41.2 -33.8 0.0064 25 37.5 -35.0 0.0020 
• Moreland, 1999 59 17 35.7 -23.3 0.0531 24 40.0 -21.5 0.0323 
• Keystone, 2004 63 34 47.1 -15.9 0.0434 8 12.5 -50.5 0.0022 
Infliximab + MTX#          
• Attract, 99-04  50 23 39.1 -10.9 0.1763 36 36.1 -13.9 0.0799 
*Bonferroni correction resulted in a P-value < 0.0045 (0.05/11) considered significant compared to 
the active drug group. •Significant (P-value < 0.0045 (0.05/11)) difference between response 
percentages of eligible and ineligible. #Maini et al presented only Paulus criteria in their articles. 
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DISCUSSION 
 
Our data confirm the impression that in clinical practice effects of anti-TNFα 
treatment are smaller than in published RCTs. In five of eleven comparisons there was 
a significant difference between the daily clinical practice data and the active drug 
group of the RCTs. Further, the data indicate that selection towards high disease 
activity in RCTs is a major explanation for the observed different efficacy. This can be 
concluded from the fact that the differences in response between the active drug 
groups and the eligible patients were smaller than the differences between the active 
drug groups and the ineligible patients. Further eligible patients had up to 44% higher 
response rates than ineligible patients. 
With respect to dosing regime and co medication a difference in the use of 
corticosteroids between daily clinical practice and RCTs was observed. In clinical 
practice fewer patients used prednisone and many patients stopped prednisone after 
starting anti-TNFα therapy. The latter might be another explanation for the lower 
efficacy of anti-TNFα in clinical practice compared to the efficacy in RCTs.  
Our results confirm the observation by Sokka and Pincus (22), who showed 
that most patients in routine care did not meet the inclusion criteria for the early RA 
trial of etanercept (ERA) and the ATTRACT study (42% and 5% did meet, 
respectively). However DREAM patients fulfilled inclusion criteria for disease activity 
more frequently, which is probably explained by the fact that their routine care 
cohorts consisted of all RA patients instead of RA patients who started anti-TNFα 
therapy. Zink and colleagues also showed that eligible patients had higher response 
rates than non-eligible patients (23).  
Wolfe and Michaud concluded that the design of RCTs exaggerate the anti-
TNFα treatment effect due to a wash-out design, patient selection and regression to 
the mean (24). This statement is confirmed by our result that daily clinical practice 
patients eligible for the RCTs have a larger response than patients ineligible for the 
RCTs. Wolfe and Michaud suggested that the efficacy of new drugs observed in RCTs 
should be corrected for the active comparators by subtracting the placebo response 
from the response in the RCT active drug group (24). This could be possible if the 
clinical effect of the placebo itself is zero. Is has been proven that this is not the case in 
subjective continues outcomes, especially measures of pain (25). Five out of seven 
ACR core set measures are subjective outcome measure or considering pain. 
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Therefore, the placebo response is a combination of the placebo effect itself and other 
effects, such as patients’ preferences and regression to the mean. These placebo effects 
are different in every trial and observational setting therefore it is not possible to 
develop an algorithm to correct the efficacy shown in RCTs for the expected 
effectiveness in daily clinical practice. Therefore we illustrate the difference between 
clinical practice and RCTs by describing the possible confounding issues and their 
magnitude as observed. 
This study has limitations. For our data collection we only counted 28 joints 
instead of 68 as in most RCTs. This might result in an overestimation of the baseline 
disease activity in the observational data because the 28 counted joints are likely to be 
the 28 joints most affected in RA (26). Next, patients in daily clinical practice are 
treated with the medication of preference. We consider it probable that this can result 
in a larger treatment effect than in RCTs (27,28). We were unable to calculate the 
exact ACR20 response criteria as was done in most selected papers. Instead, we had to 
compare the efficacy of anti-TNFα on an over- or underestimation of the ACR20 
response, which makes interpretation more difficult.  
 RCTs are the appropriate design to evaluate efficacy of new interventions. 
However, observational phase IV studies have a complementary value to investigate 
long-term side effects and efficacy, and may be useful to study effects in patients not 
typically included in phase III RCTs (27).  
This study confirms the impression that in clinical practice effects of anti-
TNFα are smaller than in published RCTs. For daily practice patients who were 
eligible for RCTs, responses were more similar to responses reached in RCTs. 
Responses were lower in patients ineligible for RCT’s. Selection towards high disease 
activity and the continued use of co-medication in RCTs are probable explanators for 
the difference in effects of anti-TNFα in clinical practice and in RCTs. 
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ABSTRACT 
 
Purpose: to evaluate the effects of adalimumab, etanercept and infliximab on disease 
activity, functional ability and quality of life and the medication costs in a naturalistic 
design. 
Methods: All patients from the Dutch Rheumatoid Arthritis Monitoring (DREAM) 
register starting on TNFα blocking agents for the first time were monitored and 
assessed by trained research nurses every three months. The primary outcome was the 
disease activity score (DAS28) course over the 12 months follow-up, analyzed by linear 
mixed models. Secondary outcomes were the Health Assessment Questionnaire 
(HAQ), EuroQol five dimensions (EQ-5D), the Short-Form 36 items (SF36) and 
medication related total costs.  
Results: The DAS28 and SF-36 physical component scale decreased in all three 
medication groups over 12 months, but the decrease was larger for both adalimumab 
and etanercept in comparison to infliximab (p<0.0001). The analyses concerning the 
HAQ and the EQ-5D showed the same (non-significant) trend, namely that at 12 
months, the functionality and quality of life was better for adalimumab and etanercept 
patients. With regard to the medication costs, infliximab treatment resulted in 
significantly higher costs over the follow-up period than treatments with either 
adalimumab or etanercept. The comparison between adalimumab and etanercept 
showed a significant difference in the 12-months DAS28 course (p=0.031). There were 
no additional indications for differences in effectiveness or costs between adalimumab 
and etanercept.  
Conclusion: The evaluation of the effectiveness and costs showed that adalimumab 
and etanercept are more or less equal and favorable compared to infliximab in the first 
year of treatment.  
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INTRODUCTION 
 
In 1997, new treatments were introduced for the management of Rheumatoid Arthritis 
(RA), which specifically target the cytokine TNFα. These agents have revolutionized 
the treatment of RA. Adalimumab and infliximab are monoclonal antibodies, whereas 
etanercept is a soluble receptor blocking TNFα. Although the TNFα blocking agents 
differ in structure, they all block TNFα (1,2) and their efficacy is considered to be 
comparable (3). Two meta-analyses compared the response percentages of the three 
TNFα blocking agents using data of published Randomized Controlled Trials (RCT) 
(4,5) and showed no difference in effectiveness. No head-to-head comparisons are 
published yet. 
However, the response observed in RCTs can be different from the response 
achieved in daily clinical practice (6,7). In daily clinical practice, patients generally are 
older, have more co-morbidities and lower disease activity. Furthermore, in daily 
practice there are more variations in dosing and co-medication, and less compliance to 
treatment. A clinical practice register is of value by providing insight in the true use of 
medication in daily practice, heterogeneity of the treated population and, ultimately, 
the related effectiveness and costs. Therefore, a comparison between anti-TNFα 
treatments in daily clinical practice provides additional information to meta-analyses 
of RCTs. Furthermore, the use of observational research data for the evaluation of the 
cost-effectiveness for reimbursement authorities is propagated (8-10). Consequently, 
the Dutch government funded a multi centre, anti-TNFα register in which RA patients 
who started for the first time with one of the anti-TNFα agents have been included. 
These data were used to compare the effects of adalimumab, etanercept and infliximab 
on disease activity, functional ability, quality of life and medication costs in patients 
who failed at least two DMARDs. 
 
METHODS 
 
Patients 
From February 2003 until September 2004, 11 rheumatology centers in the 
Netherlands started to include all RA patients who started for the first time on one of 
the anti-TNFα agents in a prospective register, further called the Dutch Rheumatoid 
Arthritis Monitoring (DREAM) register. The inclusion of patients still continues to-
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date. In the Netherlands, patients can start with an anti-TNFα treatment when they 
have at least moderate disease activity (DAS28 ≥ 3.2) and failed on at least two 
DMARDs including methotrexate (MTX) in an optimal dose of 25 mg per week. To 
get reimbursement of anti-TNFα therapy, it is obligatory for RA patients to fulfill these 
criteria. Patients in this study were not randomized to a specific treatment.  
 
Treatment 
Although dosing was at the discretion of the attending rheumatologist, generally 
patients started the treatment with the Dutch labeled doses: adalimumab 40 mg per 
two weeks; etanercept 25 mg twice weekly; and infliximab 3 mg/kg every 8 weeks after 
a loading dose (at week 0, 2 and 6). The TNFα blocking agents could be administered 
in combination with a DMARD, corticosteroids or other treatment. All start and stop 
dates, doses, changes in doses and reason for changes were registered.  
 
Outcome measures 
The baseline visit was at the moment of start with the first anti-TNFα agents. Patients’ 
characteristics like age, sex, disease duration, rheumatoid factor, previous DMARDs 
used and the presence of one or more erosions in hands or feet were registered. A 
trained research nurse assessed the patients at baseline and subsequently every three 
months. If necessary, patients were seen more frequently by the attending 
rheumatologist. Assessments included disease activity, functional ability, quality of life 
and costs. 
Disease activity was measured by the disease activity score (DAS28) (11) and 
response was measured by means of the European League Against Rheumatism 
(EULAR) response criteria (12). Functional ability was assessed by means of the 
Health Assessment Questionnaire (HAQ) (13,14). Quality of life was measured by the 
EuroQol 5 dimensions (EQ-5D) (15) utility score and the physical and the mental 
component scales (16) of the Short-Form 36 (SF-36) (17).  
Because the medication costs were considered the cost-drivers, only medication 
related resources were included in the cost analysis. Cost of anti-TNFα, DMARDs, 
corticosteroid or NSAIDs were calculated by multiplying the true doses by the price 
per mg of the particular drugs. The prices per labeled dose of three drugs were based 
on the tariff lists (September 2006) published by the Dutch Health Care Insurance 
Board. A real cost price was calculated for the in-patient clinic administration of 
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infliximab on basis of the involved personnel, materials and devices. Cost for 
overhead (35%) and housing (10%) were added to the total cost-price of the in-patient 
clinic administration according to the Dutch guidelines for cost-analyses in health 
care (18).  
 
Analyses 
Complete data of the first 12 months after start on a TNFα blocking agent were 
analyzed on an intention-to-treat (ITT) basis. This means that all patients were 
analyzed in the group of medication on which they initially started, regardless of 
whether they received or adhered that treatment for the full 12 months. Such an ITT 
was possible to perform because data collection was continued when patients had 
stopped using their initial anti-TNFα.  
Because we were interested in the evaluation of the whole 12 months after start 
with the first anti-TNFα agent, the primary outcome was the course of the DAS28 over 
the 12 months follow-up. This was analyzed by means of a linear mixed model. After 
creating an unconditional growth model that corrected for the repeated observations 
within patients using the first order autoregressive correlation structure, the factor 
‘medication’ was included as a fixed effect. Next, a random component was added to 
the medication effect to adjust for possible sampling variation due to differences at 
baseline and in the course between the medication groups. Confounders could be 
added to the model if operational. This approach was repeated for the secondary 
outcomes. 
For descriptive purposes, changes in DAS28 and HAQ from baseline and the 
EULAR response percentages were analyzed at every time point. For this analysis, 
moderate and good EULAR responders were added and counted as responders. 
Possible differences in baseline characteristics between the three agents were 
statistically tested by one-way ANOVA procedures or by non-parametric Kruskall-
Wallis tests in case of continuous outcomes and by chi-square tests for dichotomous 
outcomes. To give insight in the duration of drug use, Kaplan-Meijer survival analysis 
was performed and the medication use after withdrawing of the initially started anti-
TNFα agents was described. The difference in drug survival curves was tested by 
means of a log-rank test. 
Differences in prognostic factors for the treatment effect were considered as 
possible confounders. A propensity score was estimated on basis of the baseline values: 
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DAS28, HAQ, age, disease duration, rheumatoid factor, sex, number of previous 
DMARDs and the presence of at least one erosion. However, there were no factors 
found which could predict treatment.  
In case of missing values for the DAS28 caused by a missing value for the ESR, 
the ESR was imputed by means of linear multivariate regression using the values of the 
SW28, TEN28 and the VAS GH of the patient. 
All analyses were done using SPSS version 14.0. 
 
RESULTS 
 
Baseline values 
Between February 2003 and August 2007, 916 patients were included. In total, 707 
patients had at least 1-year follow-up and fully accessible data at time of analysis 
(August 2007). In the first year of follow-up, 33 (4.7%) patients were no longer able or 
willing to participate in the data collection. Data of these patients were used for 
analysis until the moment of exclusion. Concerning the included patients, 267 (38%) 
patients started with adalimumab, 289 (41%) with etanercept and 151 (21%) patients 
with infliximab.  
 
Table 1: Baseline characteristics in the three drug groups 
 Adalimumab 
N=267 
Etanercept 
N=289 
Infliximab 
N=151 
p-value Missing 
values (%) 
% rheumatoid factor + 81,0 71,1 77.7 0.022 1 
% female 70.0 68.9 70.2 0.939 0 
% with ≥ one erosion 71.7 65.3 72.7 0.157 1 
Age 55,1 (12,6) 54,6 (14,2) 57,8 (13,4) 0.05 0 
Disease duration (years) $ 7.7 (2.7-13.6) 6 (2.1-13.4) 7.7 (2.7-14.1) 0.356 1 
N previous DMARDs $ 3 (2-4) 3 (2-4.75) 3 (2-5) 0.385 0 
HAQ 1,3 (0,7) 1,4 (0,7) 1,4(0,7) 0.176 10 
DAS28 5,3 (1,3) 5,5 (1,2) 5,2 (1,3) 0.059 4 
Values are presented as means (standard deviation) unless stated otherwise. $ Median (inter-quartile 
range) 
 
Table 1 shows the baseline characteristics of the patients in the three drug groups. 
Patients starting with anti-TNFα had a severe disease activity and relative long disease 
duration. There were no significant differences between the three groups of patients on 
all measured baseline characteristics, except for the percentage of patient with positive 
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rheumatoid factor. However, rheumatoid factor was not considered as a confounder, 
since it was not associated with response on treatment (p=0.626).  
 
Treatment 
Figure 1 shows drug survival curves for the three medication groups. Within the 
follow-up time frame of 12 months, 22%, 21% and 31% of the patients discontinued 
the treatment with adalimumab, etanercept or infliximab, respectively. This 
percentage was significantly higher for infliximab patients compared to adalimumab 
patients (p=0.049) and etanercept patients (p=0.024). The occurrence of adverse events 
was in 48% of the patients the reason for discontinuation; in 33% this was a lack of 
efficacy and in 18% there was another not further specified reason; with no differences 
between the three groups of patients. After discontinuation of the initial anti-TNFα 
treatment, 42% of adalimumab and etanercept users switched to another anti-TNFα 
treatment and 67% of infliximab users did so. The same anti-TNFα treatment was 
rechallenged in 8%, 15% and in 2%, respectively. Another option was to start with one 
of the conventional DMARD therapies, which occurred in 27% of the adalimumab 
patients, 25% of the etanercept patients and 20% of the infliximab patients. The rest of 
patients did not start with another consecutive treatment after stopping with the initial 
anti-TNFα treatment, but they remained on their co-medication. 
 
Figure 1: Drug survival in the three treatment groups 
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Patients starting with adalimumab and etanercept did so at the registered dose in 97% 
and 98% of the cases, respectively. Infliximab patients, however, started in 80% of the 
cases with an average dose of 3 mg/kg per 8 weeks, in 18% of the cases with an average 
dose of 4 mg/kg per 8 weeks and 2% started with higher dosages. All patients who 
started with the average dose of 4 mg/ kg did so, because according to local standards 
the number of vials (coming in 100 mg) was rounded up when the patient needed 
more than 220 ml, that is a weight higher than 73 kg, in order to prevent wastage. 
Within 12 months, 7.1% and 4.8% of adalimumab and etanercept patients had a 
dose increase, whereas 31.1% of infliximab patients had a dose increase. The median of 
the 12-months averaged dose was 40 mg per two weeks for adalimumab, 50 mg per 
week for etanercept and 3.3 mg/kg per 8 weeks for infliximab. 
 
Table 2: Co-medication used and changes within 12 months 
 Concomitant use Dose decrease Discontinuation Dose increase 
DMARD     
Adalimumab (N=267) 231 (87%) 67 (29%) 63 (27%) 9 (4%) 
Etanercept (N=289) 225 (78%) 52 (23%) 61 (27%) 12 (5%) 
Infliximab (N=151) 128 (85%) 22 (17%) 35 (27%) 7 (6%) 
p-value 0.02 0.039 0.999 0.712 
Prednisone, oral     
Adalimumab (N=267) 78 (29%) 13 (17%) 15 (19%) 3 (4%) 
Etanercept (N=289) 115 (40%) 19 (16%) 27 (23%) 5 (4%) 
Infliximab (N=151) 44 (29%) 4 (9%) 9 (20%) 3 (7%) 
p-value 0.018 0.803 0.470 0.733 
Prednisone, ia or im     
Adalimumab (N=267) 31 (12%)    
Etanercept (N=289) 51 (18%)    
Infliximab (N=151) 28 (19%)    
p-value 0.076    
Abbreviations: ia=intra-articular; im=intra-muscular 
 
With regard to co-medication (Table 2), 78% to 87% (p=0.02) of the patients used at 
least one DMARD as concomitant medication. This was in 79% to 87% MTX, in favor 
of adalimumab. One-third of the patients used oral prednisone at baseline, with the 
higher percentages in the adalimumab group. Patients treated with adalimumab could 
decrease the DMARD dose (p=0.039) significantly more often than infliximab 
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patients. Twelve percent to 19% of the patients received an intramuscular or intra-
articular prednisone injection during the first 12 months, which was not significantly 
different (p=0.076). 
 
Figure 2: The mean score and 95% confidence intervals at every follow-up moment 
after start with anti-TNFα for the disease activity (A), Health Assessment 
Questionnaire (B), EuroQol utility (C) and SF-36 physical component scale. 
 
*Significant difference (< 0.05) compared to infliximab patients. †Significant difference (< 0.05) 
compared to infliximab patients. Missing values at baseline, 3, 6, 9, 12 months, respectively: DAS28, 
0.5%, 3.4%, 6.6%, 7.9%, 5.9%; HAQ, 7.7%, 6.3%, 9.1%, 10.9%, 6.8%; EQ5D, 15.0%, 18.4%, 23.6%, 
24.7%, 28.6%; SF-36 PCS, 20.2%, 21.8%, 23.6%, 24.7%, 31.3%. 
 
Primary and secondary outcomes 
Figure 2 shows mean values for the DAS28, the HAQ, the EQ-5D and the SF-36 at 
different time points. The repeated measures analyses (linear mixed model) showed 
significant differences in the DAS28 course over 12 months between infliximab and 
both adalimumab and etanercept patients (p<0.0001) and between adalimumab and 
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etanercept patients (p=0.031). The figures for the HAQ and the EQ-5D show the same 
trend: the functionality and quality of life was best for adalimumab patients. However, 
the repeated measures analyses did not show any significant differences.  
Concerning the SF-36, patients did have mental component scores comparable 
to the USA population norm without changes and therefore only the physical 
component scale is presented. The mean baseline score on the physical component 
scale was 30, which is two standard deviations worse than the USA population norm 
(16). Adalimumab and etanercept patients improved after baseline and the course 
over 12 months was significantly better (p=0.001) than the course of infliximab 
patients, as was tested by the repeated measures analyses.  
 
Table 3: Absolute differences in DAS28 and HAQ from baseline and the EULAR 
response percentages (good and moderate added) at 3, 6, 9 and 12 months 
  Adalimumab Etanercept Infliximab 
DAS28     
Baseline  5.3 (1.3) 5.5 (1.2) 5.2 (1.3) 
3 months Decrease -1.6 (1.3)* -1.5 (1.2)* -0.9 (1.5) 
 % EULAR response 76%* 74%* 57% 
6 months Decrease -1.8 (1.4)* -1.6 (1.3)* -1.1 (1.4) 
 % EULAR response 78%* 75%* 57% 
9 months Decrease -1.8 (1.4)* -1.9 (1.4)* -1.1 (1.3) 
 % EULAR response 79%* 79%* 62% 
12 months Decrease -1.8 (1.5)* -1.8 (1.4)* -1.2 (1.4) 
 % EULAR response 78%* 80%* 61% 
HAQ     
Baseline  1.3 (0.7) 1.4 (0.7) 1.4 (0.7) 
3 months Decrease -0.35 (0.5)* -0.33 (0.5)* -0.19 (0.5) 
6 months Decrease -0.42 (0.5)* -0.35 (0.5) -0.23 (0.5) 
9 months Decrease -0.40 (0.5)* -0.36 (0.6) -0.26 (0.5) 
12 months Decrease -0.42 (0.6)* -0.35 (0.6) -0.26 (0.5) 
Values are means with standard deviations between brackets unless stated otherwise. *Significant 
difference (< 0.05) compared to infliximab patients. Missing values at baseline, 3, 6, 9, 12 months, 
respectively: DAS28, 5.1%, 4.0%, 10.6%, 12.6%, 15.1%; HAQ, 9.9%, 9.2%, 12.2%, 15.6%, 16.3% 
 
Table 3 shows the outcomes with regard to the improvements on the DAS28 and the 
HAQ and the percentage of patients with an EULAR response. Adalimumab and 
etanercept patients had significant larger improvements on the DAS28 than infliximab 
patients on all measurement points. For the changes on HAQ, a significant difference 
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was noticed when adalimumab was compared with infliximab. The percentage of 
patients with a response on infliximab was significantly smaller on all time points than 
the percentage of patients with a response on adalimumab and etanercept. Occurrence 
of missing values was not different for the three medication groups.  
As mentioned before, a group of patients (N=26) was treated with a higher 
infliximab dose. Those who started with a higher dose at baseline tended to have a 
higher (p=0.065) response rate at three months (73.1% versus 53.2%) than patients 
who started with the labeled dose of 3 mg/kg. It was not possible to analyze this on 
later time points, because after three months the dose of infliximab was often 
increased as shown before. 
 
Costs 
The median Anti-TNFα, DMARDs, corticosteroids, NSAIDs and total medication 
costs with their inter-quartile ranges are presented in Table 4 for 5 categories: Ninety-
eight percent of the total costs could be ascribed to cost related to the anti-TNFα 
treatment itself. The total and anti-TNFα medication costs for infliximab were 
significant higher than these costs for adalimumab and etanercept. Note that the 
calculation of costs for infliximab comprised the costs for administration in the in-
patient clinic (€ 80,73 per administration) and the increase of dose over time to a 
median dose of 4 mg/kg per 8 weeks. Furthermore, the higher costs for infliximab 
were entirely driven by the loading infusions at week 2 and week 6. Costs made in 
later months were not significant different from the costs of adalimumab or 
etanercept. 
 
Table 4: Median values (inter-quartile ranges) of medication costs (€) in the first year 
after baseline 
 Adalimumab 
N=267 
Etanercept 
N=289 
Infliximab 
N=151 
p-value 
Anti-TNFα € 13871  
(12957 – 13872) 
€ 13938  
(12193 – 13938) 
€ 14220  
(11096 – 16997) 
< 0.0001 
DMARDs € 51 (17 – 69) € 41 (0 – 84) € 41 (14 – 68) 0.453 
Corticosteroids € 0 (0 – 7.7) € 0 (0 – 20) 0 (0 – 17) 0.002 
NSAIDs € 96 (0 – 176) € 47 (0 – 176) € 87 (0 – 211) 0.336 
Total € 13944  
(13239 - 14143) 
€ 13985  
(12323 – 14279) 
€ 14460  
(11707 – 17326) 
< 0.008 
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DISCUSSION 
 
This evaluation of the effectiveness and costs showed that adalimumab and etanercept 
revealed better outcomes compared to infliximab. Significant different effects between 
the three TNFα blockers on disease activity, the physical component scale of the SF36 
and the use of co-medication were found in favor of adalimumab and etanercept. 
Furthermore, data with regard to HAQ and the EQ-5D showed the same tendency but 
differences were not statistically significant. With regard to the medication costs, 
infliximab treatment resulted in higher costs over the follow-up period than 
treatments with either adalimumab or etanercept, mainly due to the loading gifts at 2 
and 6 weeks. There was also a difference in disease activity between adalimumab and 
etanercept in favor of adalimumab but not on any of other secondary outcomes 
measures.  
 Better effectiveness of etanercept in comparison to infliximab was 
demonstrated by one other observational study (19). Adalimumab was not studied. 
Better ACR20 response rates at the three and six months follow up and better drug 
survival was found for etanercept. Increases of the dose of infliximab were needed in 
57% of the patients in that study. Lower costs were also reported for etanercept 
monotherapy compared with infliximab combined with MTX by Nuyten et al (20).  
 The results of our study are in contrast with the results of two known meta-
analyses (4,5), from which was concluded that there are no differences in effectiveness 
between the three anti-TNFα agents. However, in both meta-analyses the effectiveness 
in all infliximab dose groups of the ATTRACT trial (21) were combined. The Dutch 
labeled dose of infliximab, analyzed in our study, is the lowest dose in the ATTRACT 
trial (21) and thus not comparable with the mean infliximab dose analyzed in both 
meta-analyses. The ATTRACT trial did not show clear (significant) differences in 
effectiveness between the four dose groups, but they did show a trend for increased 
efficacy in higher dose groups (21). Furthermore, in the present study a trend was 
shown for a higher response percentage in patients starting on a higher dose of 
infliximab. Therefore, it is very plausible that the relatively low dose of infliximab as 
analyzed in this study can be the explanation for the difference in effectiveness 
compared to adalimumab and etanercept.  
 According to guidelines for cost analyses in several (18,22) , costs should be 
calculated from a societal perspective. This would mean that besides medication, also 
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other medical consumption, traveling and absence from work should be considered. 
Travel costs could be different between the three treatment groups due to the in-
patients administration of infliximab. However travel costs were not considered as the 
cost-drivers; either were costs due to absence of paid work. Because of the severity of 
the RA and the age, most patients did not perform paid work (80% of the patients had 
either an elderly pension or an incapacity payment), which was not considered to 
change during the 12 months of follow-up. Medical consumption as a consequence of 
adverse events could have played a role. However it could not be considered in this 
study because of a lack of statistical power to evaluate a possible difference of the 
occurrence of adverse events between the agents. Long-term cost savings or benefits 
were not within the scope of the study, although it is very good possible that the 
presented differences result in differences in quality of life, functionality and costs-
savings in the future. 
 Furthermore, it should be pointed out that patients were not randomized 
between the three drug groups in this study, which could possibly lead to confounding 
by indication. Confounding by indication can play a role when there are differences at 
baseline in factors related to the outcome measure of the study. We tested possible 
differences between treatment groups at baseline in known prognostic factors for 
effectiveness like all baseline values and patient’s characteristics in which we did not 
find clinically relevant differences. Other possible factors, which might have played a 
role in the decision between the three anti-TNFα agents, are a higher baseline risk for 
side effects or the patient’s preference for one of the drugs. However it is not likely 
that these factors could have influenced the effectiveness of the drugs as measured in 
this study. The percentage of patients who stopped due to side effects was not different 
between the three agents and will not have affected the difference in effectiveness 
between the agents. Patient’s preferences for one agent could influence the 
effectiveness when a patient is not treated with a treatment of choice. However in this 
study patients were not randomized and therefore treated with the treatment of choice 
optimizing the adherence to treatment and therefore the effectiveness of treatment. At 
last, a survey afterwards revealed that the choice between the three treatments was 
mostly time and place dependent in the way that the three drugs were differently 
available or reimbursed during the inclusion period.  
We would like to emphasize that a randomized head-to-head study would be 
the best way to address the hypothesis about equal effectiveness of the three anti-
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TNFα agents from a methodological point of view (minimizing confounding). 
However, such a study is not likely to be ever performed, because there are no parties 
to fund such a study. In the absence of a randomized head-to-head comparison, in our 
opinion, this observational study provides a valid answer to the rheumatologist on the 
question which one of the three TNFα blocking agents should be prescribed. 
Observational data can even be of extra value providing data on diversity in doses, 
effectiveness and costs in clinical practice compared to RCTs. There are other 
biological registries in Europe (23-25), which could provide real life data on anti-
TNFα doses, drug survival and effectiveness. However, they did not report on the 
comparison of effectiveness between all three anti-TNFα agents. 
 
Overall, this evaluation of the effectiveness and costs showed that adalimumab and 
etanercept revealed better outcomes than infliximab in the first year of treatment. In 
future research it has to be studied whether a different dosing scheme for infliximab 
(higher doses or shorter intervals) is equally effective in daily clinical practice as 
adalimumab or etanercept.  
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ABSTRACT 
 
Objective: To study the adherence of rheumatologists with the Dutch guidelines for 
anti-TNFα treatment. The secondary objective was to evaluate alternatives of the 
present guideline with regard to the percentage of responders and costs. 
Methods: The response (> 1.2 DAS28 decrease) in patients who started on anti-TNFα 
for the first time was evaluated at three and six months after start. It was evaluated 
how many patients continued or discontinued their initial anti-TNFα treatment. 
Possible alternative guidelines were evaluated by means of a decision tree, with regard 
to the expected percentage of successfully (responders) and unsuccessfully treated 
patients and expected costs.  
Results: At three months 56% (N=306) and 44% (N=233) of all 539 evaluable patients 
were classified as responder or non-responder, respectively. Despite the guidelines, 
most (81%) (N=189) of the non-responders continued treatment. Thirty-seven 
percent of the non responders who continued anti-TNFα were eventually classified as 
responder at 6 months. Decision analytic modeling showed that with equal expected 
costs all alternative strategies would result in more responders than according to 
theoretical full adherence with the guideline. ‘Continuation in case of partial response’ 
had the best trade-off between successfully treated patients (64%) and unsuccessfully 
treated patients (17%).  
Conclusion: There was suboptimal adherence to the Dutch guidelines for treatment 
with anti-TNFα for RA patients. This seemed to be justified by the fact that a delayed 
response up to 6 months was shown. If treatment is continued despite a non-response 
at 3 months, we recommend doing this only in patients with at least a partial response 
(at least 0.6 DAS28 improvement).  
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INTRODUCTION 
 
The tumor necrosis factor alpha (TNFα) antagonists adalimumab, etanercept and 
infliximab have proven to be efficacious in several clinical trials (1-3) and have 
changed the treatment of patients with rheumatoid arthritis (RA). However, a 
treatment with one of the anti-TNFα agents is expensive with mean medication costs 
exceeding 1000 euros per month. In most European countries (4) and in the USA (5) 
there are guidelines and recommendations in order to optimize the effectiveness and 
to limit the use of anti-TNFα in clinical practice for reasons of cost. These guidelines 
all state that prescription of anti-TNFα agents should be restricted to patients with 
active RA in whom there is an insufficient response to one or two disease modifying 
anti-rheumatic drugs (DMARDs). A treatment with one of the anti-TNFα agents 
should be discontinued if there is no indication of effect within three to six months. 
The measure of effect is not explicitly defined in most guidelines and is then based on 
clinical opinion.  
In the Netherlands as well as in the United Kingdom, a decrease of DAS28 of 
more than 1.2 after 3 months had been advised for continuation of the anti-TNFα 
agent. In a recent comment on the updated guidelines of the British Society of 
Rheumatology it was questioned whether failing to decrease the DAS28 by > 1.2 after 
3 months is sufficient grounds for withdrawing therapy (6). It is, however, not 
completely clear whether continuing treatment is more effective than stopping the 
treatment and switching to another treatment option. (7) In the absence of evidence 
for the latter option, the British National Institute for Health and Clinical Excellence 
(NICE) actually recommended to stop treatment when there is no response at six 
months following initiation of anti-TNFα therapy (8). 
In general there is a lack of evidence to support development of guidelines for 
continuation of anti-TNFα. Therefore, we studied whether rheumatologists complied 
with the Dutch guidelines for anti-TNFα treatment, using the Dutch Rheumatoid 
Arthritis Monitoring (DREAM) register on anti-TNFα. Furthermore the 
consequences on disease activity, functionality, quality of life and costs were compared 
between patients who were and were not treated in adherence with the guidelines. 
Additionally, possible alternative strategies were being modeled with regard to the 
percentage of successfully (responders) and unsuccessfully treated patients and costs.  
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METHODS 
 
Patients 
Since February 2003 all consecutive RA patients who started for the first time on one 
of the anti-TNFα agents in 10 hospitals in the Netherlands have been included in a 
prospective register, further called the Dutch Rheumatoid Arthritis Monitoring 
(DREAM) register. In the Netherlands, RA patients needs to fulfill criteria in order to 
get reimbursement of anti-TNFα therapy, which are: 1) having at least a moderate 
disease activity (DAS28 ≥ 3.2) and 2) having failed on at least two DMARDs including 
methotrexate (MTX) in an optimal dose up to 25 mg per week. Anti-TNFα therapy 
may be continued if there is a decrease of at least 1.2 in the DAS28 at 3 months. A 
waiver may be acquired if there is a good reason to continue the treatment despite a 
non-response at 3 months.  
The register contains all start and stop dates, doses, changes in doses and reason 
for changes of all medication that is used by the patient. The choice of anti-TNFα 
agent, dosing and concomitant treatment was at the discretion of the attending 
rheumatologist. Data collection in the register is ongoing even when patients have 
stopped using anti-TNFα. 
 
Outcome measures 
The baseline visit took place at the moment of start with the first anti-TNFα agent. 
Patients’ characteristics like age, sex, disease duration, rheumatoid factor and previous 
DMARDs used were registered. Trained research nurses assessed the patients at 
baseline and subsequently every three months. If necessary, patients were seen more 
frequently by the attending rheumatologist.  
Disease activity was measured by the disease activity score (DAS28), combining 
the following variables: the 28 joint count for swelling (SJC28), the 28 joint count for 
tenderness (TJC28), the Erythrocyte Sedimentation Rate (ESR) and patient’s global 
health as assessed by a Visual Analogue Scale (GH) (9). In case of missing values for 
the DAS28 caused by a missing value for the ESR, the DAS28 was calculated using an 
imputed ESR. The ESR was imputed by means of linear multivariate regression using 
the values of the SJC28, TJC28 and GH of the patient.  
Because we hypothesized that benefits not captured by DAS28 such as decrease 
in functional disability or well-being were considered in the decision about 
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continuation of anti-TNFα, we also used questionnaires assessing these aspects. 
Functional ability was measured by means of the Health Assessment Questionnaire 
(HAQ) (10,11). Quality of life was measured by the EuroQol 5 dimensions (EQ-5D) 
(12) utility score and the physical and the mental component scales (13) of the Short-
Form 36 (SF-36) (14).  
Because the anti-TNFα drug and administration costs were considered the cost-
drivers, only those were included in the cost analysis. Costs were calculated by 
multiplying the applied doses by the price per mg of the particular drugs. The prices 
were based on the tariff lists (September 2006) published by the Dutch Health Care 
Insurance Board. A true cost price was calculated for the in-patient clinic 
administration of infliximab on basis of the personnel, materials and devices. Cost for 
overhead (35%) and housing (10%) were added to the total cost-price according to the 
Dutch guidelines for cost-analyses in health care (15). 
 
Analyses 
First, the percentage of patients who were treated in adherence with the guidelines was 
analyzed by calculating the percentage of patients with a response at three months and 
the discontinuation rate after three months. In order to evaluate whether the extent of 
improvement was a predictor for the decision to continue or not, the decrease in 
DAS28 was tested for a statistical significant difference between patients continuing or 
discontinuing their current anti-TNFα agent within three to six months by means of a 
student’s t-test. 
 Next, the consequence of deviating from the guideline was evaluated regarding 
disease activity, functional ability and quality of life. Three groups of patients were 
analyzed: 1) responders at three months who continue their current agent; 2) non-
responders at three months who continue their current agent; and 3) non-responders 
at three months who discontinue their current agent. The course over time of DAS28, 
HAQ, EQ-5D and the physical component scale of the SF-36 was plotted up to12 
months. Differences between the three groups were tested at the 6-months follow up 
moment by means of one-way ANOVA. The total costs for the first six months were 
tested for significant differences between the three groups by means of the non-
parametric Kruskal-Wallis test. If a patient switched within those 6 months from one 
anti-TNFα agent to another, costs of both agents were included. 
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 Finally, a decision tree was used to analyze the expected costs, percentage of 
successfully (responders) and unsuccessfully treated patient in four possible strategies 
(Figure 1). The first strategy (A) was daily clinical practice as observed in our DREAM 
registry. The second strategy (B) was full compliance to the present guideline. The 
third strategy (C) was continuation of treatment in case of at least a partial response 
(0.6 DAS28 decrease). The last strategy (D) was a treatment of six months for 
everyone with evaluation of response at six months.  
The probabilities used as input for the decision tree were calculated using the 
data of patients in the DREAM registry that actually had followed one of the strategies. 
For the full compliance strategy (B), responders who continued and non-responders 
who stopped treatment after 3 months were selected. For strategy C, patients with >= 
0.6 DAS28 decrease who continued treatment and patients with < 0.6 DAS28 increase 
who stopped treatment were selected. For the last strategy (treatment for six months 
for every patient), the patients who were treated for 6 months were selected. In all 
selected patients the response at 6 months following initiation of therapy was 
calculated.  
Each branch in the decision tree represented one of the four strategies and led to one 
of the three possible outcomes: 1) responders at three months who continued their 
current agent; 2) non-responders at three months who continued their current agent; 
and 3) non-responders at three months who stopped their current agent. Costs were 
based on the average costs as observed in clinical practice as mentioned above. The 
expected costs for every strategy (or branch) in de decision tree are then calculated by 
following the probabilities for the outcomes multiplied by the costs related to these 
outcomes.  
Model uncertainty was explored using a Monte Carlo probabilistic sensitivity 
analysis. During that procedure, the model was ran for 1000 times and each time 
values from distributions surrounding the model parameters are drawn. This provided 
a non-parametric 95% confidence interval for the expected costs, percentage of 
successfully and unsuccessfully treated patients. 
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RESULTS 
 
Patients 
A total of 625 patients started anti-TNFα from February 2003 until January 2005; 234 
on adalimumab, 254 on etanercept and 137 on infliximab. All patients completed 6 
months of follow-up, which was the timeframe of this analysis. For 49 patients, the 
occurrence of adverse events was the reason to stop their first anti-TNFα agent within 
6 months after initiation. These patients were left out of the analyses because they 
followed a different strategy. The DAS28 score was missing in 6.3% at three months 
and in 12.5% at 6 months mainly because of planning problems equally divided over 
responders and non-responders; hence missingness of these data was considered to be 
completely at random. As a result, complete data of 539 patients at three months and 
of 503 patients at 6 months was available. 
 
Figure 1: A decision tree analyzing expected costs and percentages of responders and 
non-responders in 4 strategies: clinical practice (A), full adherence to the guideline 
(B), a variation of the guideline (C) and 6 months treatment for every patient (D) 
≥ 0,6 DAS28 decrease
D: 6 months treatment for all patients
C: 0.6 threshold for continuation
B: full compliance to guideline
A: observed daily clinical practice
RA patients starting 
with first anti-TNFα
N=473
N=539
N=539
N=539
3-months
response
0.85 (241/284)
non-response
0.15 (43/284)
continueresponse
0.56 (306/539)
response
0.37 (67/182)
non-response
0.63 (115/182)
continue
0.81 (189/233)
response
0.19 (7/37)
non-response
0.81 (30/37)
stop
0.19 (44/233)
non-response
0.44 (233/539)
response
0.85 (241/284)
non-response
0.15 (43/284)
continueresponse
response
0.19 (7/37)
non-response
0.81 (30/37)
stopnon-response
response
0.78 (288/370)
non-response
0.22 (82/370)
continue
0.75 (405/539)
response
0.21 (6/29)
non-response
0.79 (23/29)
stop< 0,6 DAS28 decrease
0.25 (134/539)
response
0.66 (311/473)
non-response
0.34 (162/473)
0.45
0.08
0.14
0.24
0.02
0.07
0.45
0.08
0.09
0.38
0.59
0.17
0.05
0.20
0.66
0.34
0.53 (306/539)
0.47 (233/539)
6-months
 
The DAS28 score was missing in 6% at three months and in 12% at 6 months. This means that there is 
complete data for 539 patients at three months and for 503 patients at 6 months. 
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Compliance 
At three months 56% (306/539) of the patients were classified as responder and 44% 
(233/539) as non-responder (Figure 1). The majority (81% (189/233)) of the non-
responders continued treatment. There was no difference in the percentage of non-
responders who continued treatment within three to six months between the three 
agents (adalimumab 80%, etanercept 82% and infliximab 82% (p=0.616)). Of all 
responders at three months, indeed 96% (295/324) patients continued treatment.  
Table 1 shows the baseline characteristics of the patients in three different 
groups as defined by the response at three months and the decision to continue or not. 
The responders had a statistical significant (p<0.001) higher baseline DAS28 then the 
non-responders, possibly indicating regression to the mean. The mean decrease of 
DAS28 at three months was -0.32 (-0.21 to -0.43, 95% confidence interval) in the non-
response group who continued the current anti-TNFα agent, compared to 0.09 (-0.11 
to 0.31, 95% CI) in the non-response group who discontinued, which was significantly 
different (p-value 0.002).  
 
Table 1: Baseline characteristics in the three patient groups. 
 3-month response 
– continuation 
3-month non-response 
– continuation 
3-month non-response 
- stop 
Number of patients 295 189 44 
% rheumatoid factor positive 77.3 (225) 76.5 (143) 81.4 (35) 
% female (N) 71.5 (211) 67.2 (127) 63.6 (28) 
Age 54.8 (13.6) 56.2 (13.0) 54.7 (13.6) 
Disease duration (years) $ 6.5 (2-13) 7 (3-14) 6 (2-12) 
DAS28 5.7 (1.1) 4.7 (1.2) 5.3 (1.2) 
3 months DAS28 decrease 2.3 (0.8) 0.3 (0.8) 0.09 (0.7) 
Values are presented as means (SD), medians (inter-quartile range) $, or as percentages (number). 
 
Effects on effectiveness and costs 
At 6 months, 37% (67/182) of the non-responders at three months who continued the 
current anti-TNFα agent were eventually classified as responder, indicating a time lag 
in the effect. This late effect is visualized in Figure 2 on the disease activity as well as 
on functional ability and quality of life. However, non-responders did not perform as 
well as responders on all outcomes over time. There were no significant differences in 
most of the outcome measures between non-responders who continued or 
discontinued the current anti-TNFα agent. Concerning the SF-36, patients did have 
mental component scores comparable to the USA population norm, which did not 
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changed over the 12 months follow-up, and therefore only the physical component 
scale is presented.  
 
Figure 2: DAS28, HAQ, EQ-5D and the physical component scale of the SF-36 over time for 
the responders who continued, the non-responders who continued and the non-responders 
who stopped. 
 
 
During the use of anti-TNFα, the dose of anti-TNFα was increased in 5% (14/295) of 
the responders who continued, in 11% (21/189) of the non-responders who continued 
treatment and in 9% (4/44) of the non-responders who stopped. Patients who 
discontinued their first anti-TNFα agent because of a non-response, switched in 52% 
(23/44) of the cases to another anti-TNFα agent. Both the costs of an increased dose 
and the costs of the second anti-TNFα in the patients who switched were included in 
the costs analyses. This resulted in mean 6-months costs of €6.985 (€6785 - €7185, 
95% CI) in the initial responder group, of €7.197 (€6883 - €7510, 95% CI) in the non-
responders who continued the current anti-TNFα agent and of €5.616 (€4968 - €6263, 
95% CI) in the non-responders who discontinued. The latter group had significant 
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lower anti-TNFα costs than the other two groups (p < 0.001), but the costs were still 
rather high.  
 
Decision tree 
 
Table 2 shows the results of the Monte Carlo probabilistic sensitivity analysis 
regarding the expected costs, percentage of successfully and unsuccessfully treated 
patients in the four different analyzed strategies. There were no differences in the total 
expected costs per patients per 6 months between all alternative strategies. However 
there were some differences between the strategies on the expected percentage of 
successfully and unsuccessfully treated patients. A strategy of a treatment for 6 months 
independent of the response at three months (D) revealed the highest total percentage 
of responders (67%), but also the highest percentages of patients who were 
unsuccessfully treated with the initial anti-TNFα agent for the full six months (34%). 
The strategy of full adherence to the guideline (B) would reveal the lowest expected 
percentage of responders (56%), but on the other hand, also the lowest percentage of 
unsuccessfully treated patients (9%). There was very little difference in the expected 
percentage of responders between strategy A, C and D, but the expected percentage of 
unsuccessfully treated patients was much lower in the ‘continuation in case of partial 
response’ strategy, (C) namely 17% compared to 31% in the observed clinical practice 
(A) and 34% in ‘6 months treatment for every patient’ strategy (D). 
 
Table 2: Expected costs and expected percentages of successfully and unsuccessfully 
treated patients in four strategies as a result of the Monte Carlo probabilistic 
sensitivity analysis. (presented are means and 95% confidence intervals (CI)) 
Strategies Successfully treated 
Mean (95% CI) 
Unsuccessfully treated 
Mean (95% CI) 
Costs 
Mean (95% CI) 
Full compliance to guideline (A) 0.56 (0.50-0.63) 0.09 (0.06-0.11) €6350 (€3734-€9646) 
Observer clinical practice (B) 0.62 (0.59-0.67) 0.31 (0.27-0.35) €6979 (€4697-€9611) 
Continuation in partial 
responders (C) 
 
0.64 (0.59-0.69) 
 
0.17 (0.13-0.20) 
 
€6618 (€3991-€9588) 
Treatment for 6 months (D) 0.67 (0.61-0.70) 0.34 (0.30-0.38) €6970 (€3900-€10597) 
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DISCUSSION 
 
According to guidelines in the Netherlands, a decrease of DAS28 of more than 1.2 
within 3 months is required for continuation of the current anti-TNFα agent in the 
treatment of patients with RA. This study used a daily clinical practice registration and 
showed that response, defined as at least 1.2 points improvement on the DAS28 at 3 
months, was not reached in 44%. According to the strict interpretation of the 
guideline, those patients should have stopped the current treatment with anti-TNFα. 
However, for most (81%) of those non-responders their current anti-TNFα treatment 
was actually continued. Interestingly continuation despite a non-response at three 
months seemed to have added value since 37% of the non-responders who still 
continued their anti-TNFα agent became responders at six months of treatment. 
These patients also showed prolonged improvements on functional ability and quality 
of life. In the case of full adherence to the guideline (stopping treatment) this delayed 
effect would have been missed.  
A long drug survival time despite insufficient inflammatory control has been 
shown before (16). Potential explanations were opted but not evaluated by the 
authors, including a physician or patient perception of better efficacy than reflected in 
the DAS28 or a lack of guidelines. The first explanation was also argued by the British 
Society for Rheumatology (6). Consequently, the British NICE has updated their 
guidance on the use TNFα blocking agent for RA (8), in which they state that a 
treatment with anti-TNFα should be continued only if there is an adequate response at 
six months instead of the three months in the previous version. 
However, in case of a lack of response at three months a rheumatologist can 
also decide to switch to another treatment option. Recently, one study has been 
published in which patients with a partial response on etanercept were being 
randomized between continuation of etanercept or switching to infliximab (7). The 
authors concluded that there was a numerical trend favoring patients to switch to 
infliximab. Due to the small sample size (in total 28 patients) the results of this study 
have to be confirmed by larger studies. 
When a rheumatologist decides not to stop and switch treatment but to 
continue treatment despite a lack of response, we can recommend to do this only in 
patients with at least a partial response (DAS28 reduction>0.6). From decision 
analytic modeling it could be concluded that the option to make a decision about 
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continuation in all patients at six months revealed the most responders at six months. 
However, it would also result in the most unsuccessfully treated patients. The above 
mentioned strategy to ‘continue treatment in case of at least partial response’ would 
have the best trade-off between successfully and unsuccessfully treated patients in the 
case that this strategy is fully adhered to.   
Our study has some limitations. First, extra costs including the assessment of 
the DAS28 were not taken into account in the cost analysis because they were not 
considered as cost-drivers and were not different between patients who continue or 
stop treatment. Second, for the calculation of the response percentage in the strategy 
‘6-months treatment for all patients’ only completers were selected possibly resulting 
in an overestimation of the response percentage. As an alternative the response 
percentage in the complete unselected group of patients can be used. This percentage 
was 61%, which is equal to the response percentage estimated in strategy A and C and 
therefore it would not change our conclusions. Thirdly, for the full adherence strategy 
it was assumed in the model that the probabilities to have a response at six months, in 
case of non-response and discontinuation at three months, would be the same as for 
all non-responders who did stop treatment in daily clinical practice. However, this 
may have lead to an underestimation of this probability since the patients who did 
stop treatment after the three months non-response were patients with no 
improvement at all at three months. At last, an increased number of responders and a 
decreased number of unsuccelfully treated patients would result in an decrease of 
morbidity and ultimately quality of life. However, robust data about the long-term 
effectiveness on quality of life in all analyzed strategies would be needed, which is not 
available. 
 
It can be concluded that adherence to the present Dutch guidelines for treatment with 
anti-TNFα for RA patients is suboptimal. Rheumatologists’ behavior seemed to a 
certain extent justified by the number of patients that became responders at 6 months. 
However, it is unclear whether a switch to a next treatment would have better 
effectiveness then to continue treatment in case of non-response. It treatment is 
continued after three months, we recommend to do this only in patients with at least a 
partial response (at least 0.6 DAS28 improvement). This strategy is estimated to have 
the best ratio between successfully and un-successfully treated patients. 
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ABSTRACT 
 
Objective: Recently it was proposed to use patient self-reporting instruments instead 
of clinical, objective, measurements to assess RA patients. This assumes a constant 
association between disease activity and the self-reporting instruments. The objective 
of this study was to explore in patients with rheumatoid arthritis (RA) the association 
(in time) between disease activity and patient perception of general health, disease 
activity, pain and functional disability. 
Patients & methods: Data of 624 newly diagnosed RA patients who completed 3 
years of follow-up were used for analyses. Cross-sectional linear regression models as 
well as longitudinal regression models were estimated with a VAS measuring general 
health (VAS GH, 0=best, 100=worst) as dependent variable and the disease activity 
(DAS28) without the VAS GH as independent variable. Other dependent variables 
were VAS disease activity, pain and the Health Assessment Questionnaire (HAQ) 
Results: The DAS28 and the VAS GH were significantly associated in RA patients (p 
< 0.001). However, the explained variance was low (6.7%). From diagnosis to three 
years after the diagnosis the intercept decreased given the same regression coefficient. 
The longitudinal regression model showed that the VAS GH improved during the 
disease course independent of a change in DAS28. Analyses on the other outcome 
parameters showed similar results. 
Conclusion: The perception of health by the patient can be different with equal 
disease activity, depending on the moment in the disease course. Furthermore our 
results indicate that self-reported measures on functionality, disease activity and 
general health cannot substitute measures of disease activity in RA in longitudinal 
studies and, subsequently, both are needed to be measured. 
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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic disease, with an 
unpredictable course, varying from mild to very severe. Patients with RA mostly 
experience pain and swelling in affected joints and generalized stiffness especially in 
the morning. The disease has great influence on functional ability and quality of life. 
The goal of medical treatment of RA is to suppress disease activity, and consequently 
to prevent joint damage and enhance the patient’s quality of life.  
Patients with RA are assessed in clinical trials and clinical practice by using a 
core set of measurements, consisting of a swollen (SJC) and tender joint counts (TJC), 
acute phase reactants, physician’s global assessment of disease activity, patient’s global 
assessment of disease activity, general health and pain and the assessment of 
functional ability (1). An index of disease activity for patients with RA, the DAS28, 
can be calculated on the basis of the 28-SJC, 28-TJC, ESR and a visual analogue scale 
(VAS) for general health (2). Response to treatment can be assessed by the American 
College of Rheumatology 20 (ACR20) (3) response criteria or the European League 
Against Rheumatism (EULAR) response criteria (4).  
Recently, it was demonstrated that a combination of the Health Assessment 
Questionnaire (HAQ), VAS pain and patient global assessment (VAS or Likert scale) 
appeared to be equally informative as the ACR20 response criteria or EULAR 
response criteria for distinguishing between active treatment and placebo treatment 
(5,6). Subsequently, it was suggested to use only self-reporting instruments instead of 
physician assessed disease activity, to evaluate results of drug therapy in clinical trials, 
observational studies and in clinical practice (7). Besides the ability to discriminate 
between responders and non-responders, the instruments are very easy to apply. 
Patients can complete the instruments while waiting for the physician and the 
physician can scan them in approximately less than 30 seconds (5).  
In all fields of medicine, clinical variables are closely related to the 
pathophysiological process (i.e. blood pressure in hypertension; blood glucose 
concentration in diabetes and disease activity in RA). Implicitly, clinicians assume 
that when they improve those clinical parameters, they will improve also quality of life 
and overall well-being. When using measures of functional disability and overall well-
being for evaluation of treatment in RA, as suggested recently, it is assumed that a 
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change in inflammatory related parameters is reflected in a change in parameters of 
overall well-being. However, how valid is such an assumption? 
It is well known that standards by which individuals assess their own health 
status can change over time (8-11) and therefore, one should be cautious when using 
subjective, self-reporting instruments to evaluate treatment. Changes in health are 
accompanied by processes of readjustment, reassessment and coping (12). When a 
patient is newly diagnosed with a disease, coping and consequently adaptation to the 
disease is probably barely present. In that case, the perception of health is likely to be 
associated with the objectively measured clinical status. Later in the disease course, the 
symptoms can still be present, but the patient is better able to cope with them. In this 
case the health perception will often be better than one would expect on the basis of 
the patient’s objectively measured clinical status (13).  
The objective of this paper is to explore the association between objectively 
measured clinical status (as measured by the DAS28 excluding the VAS) and 
subjective perception of health in patients with RA. Further, the hypothesis is tested 
that later in the disease course the perception of health is better than one would expect 
on the basis of the disease activity of the patient, compared to shortly after diagnosis. 
 
PATIENTS AND METHODS 
 
Patients 
Data from two observational cohort studies of RA patients, one of the department of 
Rheumatology of the Radboud University Nijmegen Medical Centre (UMCN) and 
one of the Sint Maartenskliniek in Nijmegen (SMK), were used. Both cohorts are 
ongoing and continuously include all newly diagnosed patients with RA (disease 
duration < 1 year and no prior use of disease modifying anti-rheumatic drugs) since 
1985 in the UMCN and since 1992 in the SMK. The assessment protocols are equal for 
both cohorts. Patients are treated according to the judgment of their rheumatologists 
and are assessed every three months by a trained research nurse. A more detailed 
description of the UMCN cohort is given elsewhere (14).  
For the present analysis, data of the first three years after diagnosis have been 
used, since it was supposed that the increasing amount of joint damage later in the 
disease course would affect clinical status apart from present disease activity and thus 
becomes a potential confounding factor within our analyses (15). 
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Outcome measures 
Disease activity was used as an objective measure for the clinical status of the patient 
and was measured by the Disease Activity Score (DAS28). The DAS28 yields a score 
between zero and ten, where a higher score indicates higher activity. The DAS28 is a 
statistically derived index combining the following variables: the 28 joint count for 
swelling (SJC), the 28 joint count for tenderness (TJC), the ESR and a VAS measuring 
general health (16). The DAS28 can also be calculated without the VAS and was used 
in that form for the present analysis. 
Several self-reporting measures were available in the data set. The primary 
outcome parameter was a visual analogue scale measuring general health as perceived 
by the patient (VAS GH). Secondary outcome measures were a VAS measuring pain 
and a VAS measuring disease activity as perceived by the patient (VAS DA). All visual 
analogue scales ranged from zero to 100, where zero was the most favorable state (best 
imaginable health or no pain at all) and 100 the worst state. The HAQ was also 
included as an outcome measure. The HAQ is a 20 items questionnaire measuring 
functional disability, which results in a score between zero (no disability) and three 
(severe disability). The study cohort provided in more data on the VAS GH and the 
VAS pain than on the VAS DA and the HAQ. 
 
Statistical Analysis 
Only patients with complete follow-up have been included in the analyses. Means, 
standard deviations and percentages were calculated for demographic characteristics 
of the patients at baseline. To explore the relation between disease activity and the 
subjective perception of general health, linear regression models were estimated at 
baseline, 6, 12, 18, 24, 30 and 36 months with the VAS GH as outcome variable and 
the DAS28 as predictor.  
To investigate the hypothesis that the VAS GH observed might differ from the 
VAS GH predicted on the basis of the DAS28, the estimated regression model for 
baseline was used to predict the VAS GH for 3, 6, 9, 12, 15, 18, 24, 30, 36 months on 
the basis of the observed DAS28 at these time points. This predicted VAS GH was 
plotted with the observed VAS GH at the time points concerned.  
To test the hypothesis that the VAS GH will become better later in the disease 
course, independent of a change of disease activity (DAS28), a longitudinal regression 
model (random coefficient model) was used to determine the relation between VAS 
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GH and DAS28 over the course of the disease. A random intercept was chosen to 
account for variation in baseline values. Functional disability (Health Assessment 
Questionnaire, HAQ), sex and age at time of diagnosis were added to the model to test 
for confounding or effect modification.  
All analyses were repeated for the other outcome parameters and were 
performed using the statistical software package SAS version 8.2. 
 
RESULTS 
 
Patients 
In August 2004, 908 patients had been included in the cohort, of which 624 patients 
had complete follow-up (three years). From the 284 patients with less then three years 
follow-up, 154 patients were censored patients (i.e. included less than 3 years ago) and 
130 were lost to follow-up. Reasons for lost to follow-up were: deceased (18), 
treatment at another hospital (13), stopped involuntarily (e.g. severe co morbidities) 
(16), stopped voluntarily (e.g. no longer interested to participate, low disease activity) 
(53) and other reason for lost to follow-up (30). 
At baseline, the majority of patients were female (65.5%) and rheumatoid 
factor positive (76.8%). The mean age was 54.3 (sd 13.7) years. Baseline values were: 
DAS28 5.2 (sd 1.3); VAS GH 45.2 (sd 23.4); VAS pain 45.3 (sd 22.1); VAS DA 46.1 (sd 
23.6); and a HAQ 0.77 (sd 0.6). 
 
Results from analysis 
Figure 1 shows the results of the cross-sectional regression analyses at baseline and at 
36 months. The association between VAS GH and DAS28 was statistically significant 
(p<0.0001) at all time points, but the explained variance was low (7.6% for both 
baseline and 36 months). It was found that the β-coefficients (slopes of the regression) 
were equal, but the value of the intercept was lower in the model at 36 months. This 
means that patients reported a better general health given the same disease activity 
later in the disease course. Figure 2 shows the observed and the predicted VAS GH. 
This figure also shows that the observed VAS GH reflects a better general health than 
predicted VAS GH. 
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Figure 1: Regression analysis with VAS measuring general health as dependent 
variable and disease activity score (DAS28) as independent variable at diagnosis and 
36 months after diagnosis 
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The longitudinal regression model (table 1) showed that the DAS28 and time were 
associated with the VAS GH. Time was negatively associated with the VAS GH 
showing that general health improves during the disease course independent of the 
DAS28. The significant quadratic term of time indicates that the effect of time on VAS 
GH decreased during the disease course (i.e. after an initial improvement the decrease 
of VAS GH stabilizes, as is also shown in figure 2).  
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Figure 2: Predicted VAS general health (VAS) on the basis of the observed DAS28 
versus observed VAS (95% confident intervals) 
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Table 1: Results of the longitudinal regression model with the VAS measuring general 
health as the dependent variable 
Variable Coefficient p-value 
Model 1   
 Intercept 11.9 <0.0001 
 DAS28† 6.2 <0.0001 
 Time -0.3 0.003 
 Time2‡ 0.006 0.03 
Model 2   
 Intercept 13.4 <0.0001 
 DAS28 6.2 <0.0001 
 Time -0.29 0.005 
 Time2 0.006 0.03 
 Age -0.07 0.14 
 Sex 3.9 0.004 
Model 3   
 Intercept 19.5 <0.0001 
 DAS28 3.4 <0.0001 
 Time -0.54 0.0008 
 Time2 0.009 0.03 
 Sex 2.9 0.09 
 HAQ* 10.8 <0.0001 
†DAS28 is the disease activity score, based on 28 joint counts; ‡Time2 is a quadratic term of time; 
*HAQ is the Health Assessment Questionnaire 
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A second longitudinal regression model including covariates such as age and sex 
showed that these did not confound the relation between time and the VAS GH (table 
1). A third model showed that functional disability (HAQ) was a confounding factor 
for time as a predictor (table 1). However, time still had a substantial independent 
effect on the VAS GH. Results of all three analyses pointed in the same direction, 
namely that the general health perception becomes better after diagnosis, independent 
of disease activity in the first three years. 
Similar results of the longitudinal models for all other outcomes are shown in 
table 2. All other analyses performed with the VAS pain and the VAS DA showed the 
same results as the VAS GH (data not shown). The HAQ, however, showed conflicting 
results, namely that functional disability worsened in time despite a decrease of the 
disease activity. Figure 3 showed that it was to be expected based on the relation 
between DAS28 and the HAQ at baseline that the HAQ decreased (HAQ expected). 
Instead, the observed HAQ increased. 
 
Table 2: Results of the longitudinal regression model with the VAS pain, VAS disease 
activity and the Health Assessment Questionnaire as the dependent variable 
Variable Coefficient p-value 
VAS pain   
 Intercept 7.50 <0.0001 
 DAS28† 7.08 0.036 
 Time -0.21 0.064 
 Time2‡ 0.005 <0.0001 
VAS disease activity   
 Intercept 1.04 0.6 
 DAS28 9.12 0.07 
 Time -0.08 <0.0001 
HAQ*, model 1   
 Intercept -0.39 0.0007 
 DAS28 0.14 <0.0001 
 Time 0.002 0.016 
 Age 0.007 <0.0001 
HAQ, model 2   
 Intercept -0.27 0.26 
 DAS28 0.13 0.001 
 Time 0.004 0.03 
 M Sharp# progression 0.002 0.07 
†DAS28 is the disease activity score, based on 28 joint counts; ‡Time2 is a quadratic term of time; 
*HAQ is the Health Assessment Questionnaire; #M Sharp is the modified Sharp score for measuring 
joint destruction 
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Figure 3: Predicted Health Assessment Questionnaire (HAQ) on the basis of the 
observed DAS28 versus observed HAQ  
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Recently it was proposed to use patient self-reporting instruments instead of clinical, 
objective, measurements to assess RA patients in clinical trials, observational studies 
and also in clinical practice (17). The use of subjective, self-reporting instruments 
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disease activity and the data of self-reporting instruments. Analyses showed that there 
is an association, although weak, between subjective patient self-reporting 
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health has implications for interpreting subjective, self-reporting instrument data in 
evaluation of treatments. It emphasizes the fact that disease activity and patient’s 
perception of health, disease activity and pain should be measured both 
complementary to each other.  
time (months)
0 6 12 18 24 30 36
HA
Q
0,40
0,45
0,50
0,55
0,60
0,65
0,70
0,75
0,80
observed mean HAQ
predicted mean HAQ
worst 
functionality
best 
functionality
120 
 
An important goal in managing RA is to prevent or control joint damage and 
loss of function and decrease pain (18). Recently it was demonstrated that a 
therapeutic strategy aiming for tight control of disease activity (measured with the 
original DAS) improved disease activity, radiographic disease progression, physical 
functioning and quality of life compared to routine outpatient care (19). It is 
unknown what the effect of a treatment strategy aiming for improving patient’s 
perception of general health or functional ability on joint damage or disease activity 
later in the disease course will be. There is broad agreement on the fact that the goal of 
medical treatment should be suppressing disease activity and preventing joint damage. 
However, patients’ self-reported well-being, pain and disease activity are of major 
concern in making treatment decisions. 
The incongruence over time between objectively measured and self-reported 
health might be associated with response-shift effects (10). Possible causes of such a 
response shift might be adaptation and coping strategies, social comparison (20), 
information bias in time (learning processes) (21) or a change in expectations (22). At 
presentation of a disease (for instance RA), there will be great anxiety about the future 
prospects and the unknown course of the disease, which will reflect in measures of 
well-being. After a few months, patients have learned about the treatment options and 
their prospects, they start to cope to their disease and subconsciously compare 
themselves to other RA patients. Standards by which individuals assess their own 
health status are dynamic and therefore response shift processes as described here can 
occur with every life event going through by an individual patient.  
Further, general health is an encompassing construct, of which disease activity 
is only one aspect. Other factors like social functioning, fatigue and depression play a 
part in general health and are not captured by the DAS28. This applies more or less 
also to self-reported disease activity and pain and functionality. Recent randomized 
controlled trials in the field of rheumatology including all core-set measures as well as 
measures of overall well-being showed a smaller effect on health related quality of life 
measures than on disease activity measures (23,24). Together, this is why self-reported 
measures of functionality, disease activity and general health cannot substitute 
measures of disease activity in RA and, subsequently, are needed to be measured both. 
Analyses with the HAQ as an outcome parameter showed conflicting results. 
One explanation might be that the HAQ is a more objective self-reporting 
questionnaire and is therefore less susceptible for possible response shift effects. 
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Second, joint destruction could affect the functional disability besides disease activity. 
Analyses showed that the effect of joint destruction on the HAQ almost reached 
significance (p=0.07). A last possible explanation for the increase in HAQ, despite a 
decrease in the disease activity, could be that the HAQ increases with increasing age as 
well as in the RA population as in the general population (25). 
Some shortcomings concerning this study should be mentioned. First, the 
DAS28 is used as the only objective variable associated with the patient’s subjective 
general health assessments. This was chosen because the purpose of this study was to 
explore the relation between objective and subjective measures in RA and in our 
opinion the DAS28 is the most objective measure in this field. Further, it is possible 
that other variables are associated with the perception of general health in RA patients 
as well, however longitudinal regression including variables like sex, age and 
functional disability did not change the independent association between time and 
VAS in either magnitude or direction. Finally, there was less data available on the VAS 
DA and the HAQ, so results of analyses with these parameters are less robust. 
 
It can be concluded that the perception of health by the patient can be different with 
equal disease activity, depending on the moment in the disease course. Furthermore 
our results indicate that self-reported measures on functionality, disease activity and 
general health cannot substitute measures of disease activity in RA in longitudinal 
studies and, subsequently, both are needed to be measured. 
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ABSTRACT 
 
Background: improvements in health lead patients to re-assess former health states as 
worse than initially rated (response shift). This shift might be related to prospect 
theory. According to prospect theory, response shift should also occur when health 
declines so that patients re-rate their former health state as better.  
Objective: We explored the relationship between response shifts and direction of 
disease change by relating subjective change to objective change. 
Methods: Baseline and three month follow-up data from a cohort of rheumatoid 
arthritis patients starting on TNFα blocking agents were used. Objective disease 
change was classified according to a disease-specific outcome measure (DAS28). 
Visual analogue scales (VAS) for general health (GH) and Pain were used as self-
reported measures. Three months after starting on anti-TNFα patients used the then-
test to re-rate their baseline health with regard to general health and pain. A response 
shift was calculated by subtracting the then-test value from the baseline value. 
Results: At three months, 49 (44.1%) patients were classified as responder and 62 
(55.9%) as non-responder on the DAS28. Response shifts on the VAS GH and VAS 
Pain were negative and similarly sized in responders and non-responders.  
Conclusion: Response shifts were not related to the direction of disease change. Using 
the then-test as a baseline measure, led to the paradoxical result that clinical non-
responders increase significantly on a self-reported measure. Implicit theory of change 
is superior to prospect theory in describing our results and conflicting results in the 
literature.  
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INTRODUCTION 
 
Over the past two decades there has been an increase in the use of patients’ self-
reported outcomes, such as quality of life measures, in evaluative studies and daily 
clinical practice in the medical field. In general, to compare assessments over time and 
between individuals, it is a prerequisite of a measurement that the patient’s concept of 
the subject of assessment is the same in all situations. However, there are many 
examples of discrepancies in ratings of a health state between patients and proxies (1-
4) and within a single patient over time (5-12), which challenge the use of self-
reporting outcomes. It is shown in a variety of disorders that patients who improved 
on their health re-assessed their former health state as worse than initially rated (5-
13). Furthermore, in cancer patients the relative importance of different domains of 
quality of life varied over time (14). Finally, there are many examples in which it is 
demonstrated that patients value a certain health state differently than individuals not 
in that health state (1-4).  
In response shift theory, these findings are interpreted (15) as follows: patients 
do not rate their own health in reference to an absolute standard but in reference to a 
relative standard. In health related subjective measures, this relative standard is 
tentatively taken as the patient’s own current health state. However, current health, 
and therefore an individual’s standard may differ between patients and can also 
change over time (15-17). This can lead to different (e)valuations of the same health 
state at different moments in time. Some authors suggest that self-reported outcomes 
should be corrected for changes in relative standards (18,19) by for instance a then-
test (18). 
Prospect theory can be used to quantify this reasoning (20,21). Prospect theory 
is originally developed in the context of gambles for money and is a theory about 
decisions under risk (22). Prospect theory defines gains and losses relative to a reference 
point. Different frames are assumed to shift the reference point along the outcome 
dimension, altering the location of a S-shaped value function (23). Like Treadwell and 
Lenert (21), we applied this theory to valuing health. In valuing health the reference 
point of the S-shape value functions can be described as an individual’s current health. 
Figure 1 shows two of those S-shape value functions for two different health states in 
time, A and B. The x-axis represents the health state and the y-axis represents the 
subjective value of that health state relative to that health state. The S-shape function 
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represents the value function according to the current health state. When a patient 
improves in health (moves from A to B), his value function shifts to B. According to 
the shifted S-shape value function, the former state is rated as worse (A’) than 
previously (A). 
Following prospect theory, it seems reasonable to assume that declines in 
health, would lead patients to retrospectively rate their former health as better than 
initially rated. Again referring to Figure 1, when a patient deteriorates in health 
(moves from B to A), his value function shifts to the left. According to that function 
the former health state will be rated as better (B’) than previously (B). When a health 
state remains stable, no shift in the value function is expected. Sound evidence for 
these predictions has not yet been reported in literature. The aim of this study was to 
test these predictions in patients with severe and prolonged rheumatoid arthritis. 
 
Figure 1: Two S-shape value functions for two different health states in time 
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METHODS 
 
Study site and subjects 
A population of chronically ill rheumatoid arthritis patients receiving anti-TNFα 
treatment was used to explore the relationship of shifts in internal standards with the 
direction of disease change. Data from a prospective registry was used. Since February 
2003 all rheumatoid arthritis patients, from 11 Dutch centres, who started on an anti-
TNFα agent (either adalimumab, etanercept or infliximab) for the first time, were 
included in this registry (24). The primary aim of this registry is to evaluate and 
monitor anti-TNFα treatment in rheumatoid arthritis patients. Since January 2004 
then-tests were included in this registry.  
 
Study design and outcome measures 
Patients’ baseline characteristics were registered at the start of the first anti-TNFα 
treatment. These characteristics included: age, gender, weight, disease duration, 
rheumatic factor status, the presence of one or more erosions in hand or feet and 
number of previous DMARDs used. In addition to these characteristics, the three 
main measures for this study, disease activity, the patient’s self-perceived general 
health and self-perceived pain, were registered at baseline and three-month follow-up 
assessments.  
For this study, disease change was assessed with the European League Against 
Rheumatism (EULAR) response criteria, because these have shown good construct, 
criterion and discriminant validity (25). The EULAR criteria are based on the Disease 
Activity Score 28 (DAS28), which is a statistically, derived index combining the 
following variables: the 28 joint count for swelling (SW28), the 28 joint count for 
tenderness (TEN28) and the Erythrocyte Sedimentation Rate (ESR). As a valid 
alternative to ESR, C-reactive Protein (CRP) scores were used in case of missing ESR 
values (26). The EULAR response criteria combine change and an absolute level of 
attained disease activity (Table 1). By this definition, the non-response group is a 
mixture of patients who do not improve relevantly and patients who deteriorate. 
Additionally, patients who deteriorate relevantly, defined as at least one population 
standard deviation decline, were analysed as a subgroup.  
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Table 1: EULAR response criteria (good, moderate, non-response). 
Present DAS28 Change in DAS28 
> 1.2 >0.6 en ≤ 1.2 ≤ 0.6 
DAS28 ≤ 3.2                      (low) Good Moderate Non-response 
3.2 < DAS28 ≤ 5.1   (moderate) Moderate Moderate Non-response 
DAS28 > 5.1                     (high) Moderate Non-response Non-response 
 
The patients’ self-perceived general health and pain were assessed on a 100mm Visual 
Analogue Scale (VAS GH and VAS Pain). Patients were asked to rate their health or 
pain by drawing a vertical line on the horizontal presented scale, indicating the 
perceived amount of health or pain. Outcomes on this scale range from zero to one 
hundred, where a score of zero indicates a worst imaginable general health state or 
extreme pain, and a score of one hundred indicates best imaginable general health 
state or no pain. Patients were asked to rate their current general health and at 
baseline and at three months follow-up. At three months the patients were also asked 
to retrospectively re-rate the baseline general health and pain by means of a then-test 
(18,27). Patients were specifically instructed not to try and remember what they 
scored at baseline (recall), but to re-assess their health and pain at baseline from their 
current perspective.  
 
Statistical analysis 
Descriptives of baseline characteristics were calculated. Then, response shifts were 
calculated as then-test VAS scores minus baseline VAS scores. Changes over time in 
VAS scores were calculated as prospective change and corrected change. The 
prospective change was calculated by subtracting baseline scores from three-month 
follow-up scores; corrected change was calculated by subtracting then-test scores 
(considering this as a corrected baseline score) from the three-month follow-up 
scores.  
The relationship of shifts in internal standards with the direction of disease 
change was investigated by dividing patients into two groups depending on their 
objectively determined EULAR response status at the three-month follow-up 
moment. To enhance the contrast in clinical disease change between groups, patients 
classified as moderate responders were left out of the analysis. Baseline characteristics 
were tested for equivalency between groups by means of Chi-square tests, 
independent samples t-tests and Mann-Whitney U tests. The mean response shift and 
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the mean changes in VAS general health and VAS Pain were tested for statistical 
significance using one-sample t-tests. Mean response shift and mean changes in 
perceived general health and pain were compared between groups using independent 
samples t-tests. All analyses were performed using the statistical software package 
SPSS 14.0.2 (SPSS Inc., Chicago, IL.) 
 
RESULTS 
 
Between January 2004 and December 2006, 212 patients had complete three-month 
follow-up data. We excluded 83 moderate responders; 18 other patients were excluded 
from the analysis due to missing DAS28 or VAS data. Baseline characteristics of 
excluded patients did not differ from included patients. Thus, 111 patients remained 
for the analyses: 49 (44.1%) patients were classified as a responder to the anti-TNFα 
therapy and 62 patients (55.9%) were classified as a non-responder to therapy. On the 
DAS28, responders had a mean improvement of 2.2 points (ranging from 1.2 to 4.5) 
and non-responders had no improvement (mean -0.05 (ranging from -3.0 to 1.1)). 
Table 2 shows the baseline characteristics of clinically responding and non-
responding patients. These data show that clinically classified responders did not 
differ from non-responders at baseline. 
 
Table 2. Baseline characteristics of patients grouped by response classification 
 DAS28 Responder DAS28 Non-responder p-value 
Age 51.5 (13.0) 54.9 (15.7) 0.235 
HAQ 1.2 (0.6) 1.3 (0.7) 0.329 
DAS28 4.5(0.9) 4.6(1.3) 0.828 
Disease duration* 6.0 (11.8) 6.0 (8.0) 0.896 
Number of previous DMARDs* 3.0 (2.0) 3.0 (2.0) 0.272 
% female 71.4 62.9 0.344 
% with ≥ one erosion 76.6 63.3 0.140 
% positive rheuma factor 70.8 71.0 0.988 
Values are presented as mean (standard deviation) unless stated otherwise. * median (interquartile 
range) 
 
Prospective change 
Table 3 and the figures 2 and 3 show the changes in VAS scores on both general health 
(Figure 2) and pain (Figure 3). On average, clinical objective responders to therapy 
scored 31 points improvement on VAS general health, which was statistically 
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significant and significantly more than the average 9.3 points improvement that was 
reported by non-responders. On the VAS Pain, responders scored a significant mean 
improvement of 31.8 points, whereas non-responders reported an insignificant 
improvement of 6.0 points.  
 
Figure 2: Changes in VAS general health scores of patients responding to therapy 
versus patients not responding to therapy. 
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Note that a score of zero indicates a worst imaginable general health state and a score of one hundred 
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Figure 3: Changes in VAS Pain scores of patients responding to therapy versus 
patients not responding to therapy. 
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Response shifts 
Objectively classified responders and non-responders showed a significant negative 
response shift (lower then-test values than baseline values) on both scales (Figure 2 
and 3). The identified response shifts were of equal size for responders and non-
responders (Table 3).  
 
Table 3. The prospective change (three months minus baseline) and the response shift 
(then-test minus baseline value) for the VAS general health (GH) and Pain for 
responders and non-responders. 
 DAS28 Responder DAS28 Non-responder Mean difference* 
Prospective change VAS GH 31.0 (22.7; 39.3) 9.3 (2.5;16.1) 21.7 (32.2; 11.2) 
Prospective change VAS Pain 31.8 (24.8; 38.8) 6.0 (-0.4;12.4) 25.8 (35.2; 16.4) 
    
Response shift VAS GH -9.7 (-16.2; -3.2) -6.8 (-12.6; -0.9) -2.9 (-11.6; 5.7) 
Response shift VAS Pain -10.7 (-18.3; -3.2) -10.9 (-16.4; -5.5) 0.2 (-8.8; 9.2) 
*mean difference between responders and non-responders. Values are presented as mean (95% CI) 
 
Corrected change 
The calculated mean corrected change in VAS scores are also shown in figures 2 and 
3. When applying this corrected measure, clinical responders to therapy averaged a 
40.7-point improvement on VAS general health, which was statistically significant and 
significantly more than the average 16.1-point improvement of the non-responders. 
Outcomes of the VAS Pain show similar results. Responders averaged a 42.6-point 
improvement, compared to a significantly lower improvement of 16.9-points for non-
responders. 
 
Patients who deteriorate in health 
A group of 11 patients deteriorated significantly on the DAS28. Those 11 deteriorated 
patients had a significant mean negative response shift on general health of -14.5 (95% 
CI –28.3; -0.8) and on pain of -19.1 (95% CI –36.9; -1.3). 
 
DISCUSSION  
The purpose of this study was to test the prediction that response shift is dependent 
on the direction of a clinical disease change. This study showed that both responders 
and non-responders, when asked 3 months later with a then-test, on the average rated 
their baseline health state as worse than actually rated at baseline. Furthermore, 
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paradoxical results occurred when the then-test was applied with the purpose to 
correct for a shift in internal standards; for clinically stable or deteriorating patients 
an even greater improvement in health would be calculated when using then-test 
rating as compared to using the prospective rating (figures 2 and 3).  
For the responders, our negative response shifts were in line with the 
predictions derived from prospect theory and they complied with the large amount of 
literature reporting on negative response shifts in patients who improve on their 
health(5-12). Our negative response shifts in non-responders conflicted with the 
prediction derived form prospect theory. Only two studies assessed both patients who 
improved, who did not improve, or who even deteriorated in health, of which one 
complies (28) and one does not comply (5) with prospect theory. Ahmed and 
colleagues (5) used objective criteria to determine the direction of disease change, like 
we did. In agreement with our study, they found mean response shifts with a similar 
direction in 196 participants. These response shifts were independent on the direction 
of the disease change that had occurred and conflict with the results of Janssen et al. 
They investigated response shift in 46 patients were the disease change was defined 
with a subjective change question. In contrast to Ahmed’s and our findings, their 
response shifts indeed depended on the direction of the disease changes (28). The 
explanation for these conflicting findings may be the crucial difference in the way that 
the disease change was defined: objective (Ahmed’s and our study) versus subjective 
(Janssen’s study).  
The implicit theory of change is a promising candidate to explain all conflicting 
findings. This theory originates in the psychological research and describes that 
individuals might be unable to accurately remember a former situation but apply an 
implicit theory of change, instead, to construct that former situation (29). In general, 
individuals start by assessing their current status and work back from this point, 
applying an implicit theory of change, to determine what their baseline state must 
have been. This implicit change is the key concept of a reconstruction process.  
When applying this theory in health, we are able to explain the conflicting 
results as described before. In our study and the study by Ahmed et al (5), non-
responders showed no objective disease change, but the treatment received could have 
led to an implicit theory of positive change. Working back from their health status, 
this implicit theory of positive change led patients to re-rate their baseline health 
status (then-test) as worse than their initial baseline rating. In the study by Jansen et al 
136 
(28) patients self-reported a subjective disease change. Working back from their 
health status, they could have applied this implicit theory of negative change to re-rate 
the baseline health status with the then-test as better than their initial baseline rating. 
In summary, an implicit theory positive change of patients in our and Ahmed’s study 
and the implicit theory negative change of patients in Janssen’s study can explain the 
conflicting the response shifts.  
Some shortcomings concerning this study should be mentioned. By using the 
EULAR criteria to define disease change (Table 1), the non-response group was a 
mixture of patients who did not improve relevantly and patients who deteriorated. A 
subgroup of 11 patients who deteriorated on the objective measure DAS28 was 
analyzed. Even those 11 deteriorated patients showed a significant negative response 
shift on general health and pain, rating their baseline health state worse than initially 
rated. Again, this is not in line with prospect theory. Another limitation is that the 
patients’ memory or perceptions of change were not assessed and therefore the 
implicit perception of change could not be assessed.  
In conclusion, the similar direction and magnitude of response shifts in objectively 
defined responding and non-responding patients, suggests that these shifts are not 
related to the direction of disease change. Furthermore, correcting for response shifts 
by rating with the same internal standards, leads to a paradox in which clinical non-
responders increase significantly on a self-reported measure. Implicit theory of change 
is superior to prospect theory in describing our results and conflicting results in the 
literature. 
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The objective of this thesis was to explore the value and the validity of data collected in 
daily clinical practice for drug evaluation and cost-effectiveness studies, using data on 
TNFα blocking agents in rheumatoid arthritis. First, the need for information from 
daily clinical practice was researched. Then, the value of daily clinical practice data 
was illustrated by analysing two clinical research questions using the daily clinical 
practice data. To collect data in daily clinical practice on a large scale, a valid and easy 
to use evaluation instrument is needed. It was recently suggested to use patient self-
reported measures to monitor patients and to evaluate results from therapy. The last 
two chapters of this thesis deal with this issue. Specifically, they addressed the 
phenomenon of response shift that might bias the results of such self reported 
measures and the possibility to correct for the occurrence of response shifts.  
 
Conditional reimbursement 
Reimbursement authorities in several countries are considering to use daily clinical 
practice data for coverage and payment decisions (1-3) because the external validity of 
RCT data and pharmaco-economic models based on those data are questioned (4-8). 
In the Netherlands, authorities are developing legislation for reimbursement decisions 
(9). A provisional license for reimbursement will be provided on the basis of favorable 
results from a pharmaco-economic modeling study or a pharmaco-economic study 
alongside a RCT. Then, additional (pharmaco-economic) data have to be collected in 
clinical practice over three years including drug survival, effectiveness rather than 
efficacy and costs based on true doses. A decision about a definitive license for 
reimbursement will be based on those data. It is shown in this thesis that indeed the 
prescription and consequently the use of anti-TNFα treatment in daily practice 
differed from the use in clinical trials, which indicates that cost-effectiveness 
estimations from trials might not hold in daily clinical practice. 
 
TNFα blocking agents for RA daily clinical practice  
In Chapter 3, we showed that the efficacy of TNFα blocking agents in RCTs exceeded 
the effectiveness of these drugs in clinical practice. In clinical practice more patients 
with lower disease activity were treated with TNFα blocking agents compared with 
those treated in RCTs. For daily practice patients who fulfilled the inclusion criteria 
for RCTs, responses were similar to responses shown in RCTs. Thus, in daily clinical 
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practice anti-TNFα was less effective because patients with milder disease activity were 
additionally treated. 
Then, evaluating clinical practice showed that the registered dose is increased 
in 5% to 31% of the patients, depending on the specific anti-TNFα agent, resulting in 
much higher costs than the estimated RCT protocol driven costs (Chapter 4). In the 
same chapter, an indirect comparison of results indicated that the time of drug use is 
longer than would be appropriate on basis of the response to therapy and as suggested 
in the guideline. This is confirmed in Chapter 5, in which it is demonstrated that 70% 
of all non-responders at three months continued treatment, where the guideline 
advises to stop treatment. Overall, the mean scores on disease activity, functionality 
and quality of life were worse in those patients who did not adhere to the guidelines 
compared to those who did adhere to the guidelines. However, 40% of the patients 
who continued treatment despite a non-response at three months were responders at 
six months. This indicates that the decision to continue treatment despite a non-
response at three months and thus not to adhere to the guideline, seemed to a certain 
extent justified (from a clinical point of view). 
 In summary, from our daily clinical practice evaluation can be concluded that, 
in daily clinical practice, anti-TNFα was provided to patients with milder disease, 
resulting in less effectiveness compared to RCT’s. Furthermore, the clinical pathway 
was different from that researched in RCT’s. However, this behavior influenced 6 
months effects positively. At last, the dosing scheme, specifically for infliximab, was 
used flexible. 
 These findings illustrate the added value of daily clinical practice data: 1) Daily 
clinical practice data give an indication of the incidence and prevalence of patients 
using a specific drug; 2) the population that is treated with the specific drug can be 
described compared to RCT patients and the guideline; 3) the doses and time of use of 
both the new drug and co-medication can be evaluated. Combined, this information 
can be used to estimate the budget impact of implementing a new drug in daily 
clinical practice. Furthermore, a daily clinical practice registry can be used to monitor 
the occurrence of (long-term) adverse events, which are often not reported in RCTs. 
However, the observation time in the DREAM registry is not sufficient yet to illustrate 
that point.  
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Implications on incremental cost-effectiveness ratio 
Then, an important question arises: do these differences between daily clinical 
practice and RCT data influence earlier reported cost-effectiveness ratio’s and 
moreover would this lead to a different decision on reimbursement based on daily 
clinical practice data? To answer this question, the daily clinical practice data should 
be incorporated into the original cost-effectiveness analysis or a new comparison 
using observational data has to be performed. 
To illustrate how differences in clinical practice influence results from cost-
effectiveness evaluations, a published pharmaco-economic model (10,11) was adapted 
by us and re-analyzed with daily clinical practice data. The original pharmaco-
economic model, based on Markov chain analysis, compared a treatment with anti-
TNFα to usual care or to the relatively new DMARD, leflunomide. For the anti-TNFα 
branch (Figure 1 A), data from two placebo controlled RCTs were used. For the 
purpose of this illustration, the original anti-TNFα branch (with RCT data as input) 
was copied and adapted if necessary. But in this copied branch only daily clinical 
practice data was used. In this way insight was gained about the difference between 
RCT data and daily clinical practice data concerning the incremental costs-
effectiveness ratio.  
 
Table 1: results of the Markov analyses for the original model and two variation of the 
model 
Strategy Costs (€) Effect (QALY’s) Incremental C/E 
Usual care € 15.383 3,145  
Anti-TNFα RCT input € 68.374 3,323 € 297.699 
Anti-TNFα DCP input € 60.542 3,287 € 318.015 
Anti-TNFα DCP input  
and DCP clinical pathway 
€ 73.834 3,373 € 256.364 
*The structure is adapted according to chapter 5: 70% of the patients  
who are a non-responder do continue treatment. (Figure 2) 
 
First, the effectiveness as measured in daily clinical practice (Chapter 3) was used in 
the original model. The structure of the model stayed the same, but the response rate, 
the initial distribution of the DAS Markov states, and the transition probabilities were 
based on daily clinical practice data. In this case, the anti-TNFα strategy was estimated 
to be less effective, but also less expensive (Table 1) compared to the original anti-
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TNFα arm with RCT-based input data. Compared to usual care, the incremental cost-
effectiveness ratio differs, being € 318 015 per QALY gained, instead of € 297 699 per 
QALY gained in the original model. 
 
Figure 1: Graphical illustration of the original model (A) and the adapted model (B) 
anti-TNFα treatment
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at 3 months
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anti-TNFα treatment
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at 3 months
Responder 
at 3 months M
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Low DAS
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Remission
Continue treatment
Stop treatment Usual care
B
M
M
The structure of the Markov process is similar at every Markov node (M).  
The different probabilities used as input were dependent on the analyzed situation. 
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Next, according to the results of Chapter 5, the structure of the model was also 
adapted in such a way that patients who did not have a response to therapy at three 
months had a probability to continue treatment or to stop anti-TNFα treatment and 
start with usual care (Figure 1 B). This strategy was estimated to be more expensive 
but also more effective (Table 1) compared to usual care and compared to the original 
anti-TNFα arm with RCT-based input data. Compared to usual care the incremental 
cost-effectiveness ratio was more favorable than the ratio of the original model.  
According to Chapter 4, the dosage of anti-TNFα was increased in 5% to 31% 
of the patients, dependant on the type of anti-TNFα prescribed. This resulted in a 
median of € 14000 per patient per year with a maximum of € 17000 per patient per 
year. With a one-way sensitivity analysis, it was estimated what the influence would be 
of the increase of costs to € 17000 per patient per year. The influence was largest in the 
adapted structure of the model (most anti-TNFα provided), with a maximum cost-
effectiveness ratio of € 325.130 per QALY gained compared to usual care. 
 In summary, these variations in the model input and structure give an 
indication of the efficiency losses or gains as a result of differences in the clinical 
pathway of anti-TNFα use in RA patients between daily clinical practice and RCTs. In 
this case the decision based on the cost-effectiveness ratio would not change, but this 
is predominantly because of the extremely unfavorable ratios throughout the models. 
If the cost-effectiveness ratio’s of both the RCT-based or daily clinical practice based 
models would range around a critical value of for instance €80 000 per QALY gained 
(12), the decision might change. However, on which model should then the decision 
be based? 
 
Internal versus external validity 
In general, a randomized controlled trial (RCT), and not an observational study, is the 
best way to address relative (cost-)effectiveness. Some authors suggest that it is 
possible in observational studies to correct for differences in important prognostic 
factors with either multiple regression analyses or a propensity score (13-15). 
However, critics argue that it is not possible to correct for confounding by indication, 
because the choice between treatment options is an implicit choice. By definition, it is 
not possible to correct for unforeseen and not-measured confounding factors. This 
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pleads for the use of RCT data, but then the problem of poor generalizability of RCT 
based pharmaco-economic models is not solved. 
 A solution could be a pragmatic randomized trial. In a pragmatic randomized 
trial, patients are being randomized at baseline (16) but they are not being selected by 
stringent inclusion criteria and after the randomization the treatment is not 
protocolized but at the discretion of the attending physician. This might be an 
acceptable consensus balancing internal validity due to baseline balance and external 
validity due to the lack of strict inclusion criteria, protocolized treatment strategy and 
blinding. In the legislation for conditional reimbursement this would mean that 
updating the original model with DCP data of the new intervention is not enough. A 
new study should be performed, collecting data on the new intervention as well as the 
comparator. 
 
Best comparator? 
In cost-effectiveness studies the comparator should be coherent to the opportunity 
costs principle; i.e. the first best alternative treatment. In the original model as 
described above, the anti-TNFα strategy was compared to usual care or the DMARD 
leflunomide. In that time, usual care’ meant a treatment with methotrexate, 
sulfasalazine or a combination of both. Nowadays, this is not the first best alternative 
treatment. Since 1997, anti-TNFα agents have been revolutionizing the treatment of 
RA patients and are therefore becoming usual care. The important question is no 
longer whether anti-TNFα agents are cost-effective compared to conventional 
DMARDs, but what sequence and combination of medication, including anti-TNFα 
agents, is most cost-effective considering the wide spectrum of RA related medication.  
The BEST (17) study performed in Leiden, the Netherlands, is one of the 
examples investigating the place of anti-TNFα agents in the treatment of RA. In this 
study, is was shown that starting a combination of conventional DMARDs in early RA 
patients combined with strict monitoring of disease is as effective as starting with anti-
TNFα agent. However modeling showed that anti-TNFα agents had an additional 
effect on preventing joint damage resulting in favorable effects on quality of life, 
functionality and work capacity in later years. Future research from long-term follow-
up observational studies should confirm these results before implementing this 
strategy in daily clinical practice. 
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Self-reporting measures for monitoring 
The last two chapters of this thesis addressed two issues concerning the use of 
subjective patient outcomes in daily clinical practice to evaluate effectiveness of anti-
TNFα in daily clinical practice. Presently the evaluation of effectiveness of drugs 
depends largely on measurement with the disease activity score (DAS28). However, 
the DAS28, and in particular the joint count, are criticised for a low inter-observer 
variability (18), the discrepancy with physician judgement (19) and the time-
consuming joint counts (20). A patients self-reporting measure could be a solution to 
measure disease activity in a large group of patients like in patients registries because 
it is claimed to have the ability to discriminate between responders and non-
responders and to be very easy to apply (21). Recently, indices based on patient 
reported outcomes are suggested like the RAPID3 and RAPID4 (22). 
However, in Chapter 6 and 7 it was shown that the subjective valuing of the 
same clinical disease states changes over time. This was concluded from the finding 
that later in the disease course the patients’ perception of general health is better given 
the same disease activity as compared to shortly after diagnosis. Similar results were 
seen from analyses with the VAS pain and the VAS disease activity as an outcome 
measure. These discrepancies can be interpreted as response shifts (23-25). Some 
authors suggest that self-reported outcomes should be corrected for the occurrence of 
response shifts (26,27). However, it can be questioned whether the difficulties of self-
report measures can be overcome.  
In the research described in Chapter 7, patients were asked to re-rate the 
baseline health state (before the start with anti-TNFα) from the perspective after three 
months of treatment. Then, at three months, both the baseline state and the three 
months state are valued with the same internal standard and the prospectively 
measured change was calculated with those ratings. However, this led to paradoxical 
results because clinically stable patients showed a great improvement in health when 
corrected for response shift. This resulted in a discrepancy between objective health 
change and subjective health change.  
Response shifts may not occur in all patient reported outcomes used in 
rheumatoid arthritis. In this thesis we addressed response shifts in visual analogue 
scales often used in the evaluation of drug effectiveness. The indices RAPID3 and 
RAPID4 combine a shortened Health Assessment Questionnaire (HAQ) and VAS 
scales (RAPID3) and patient self-assessed joint counts (RAPID4) (22). It seems likely 
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that response shift also occur in these measures, however it cannot be claimed entirely, 
whereas we couldn’t confirm a response shift phenomenon in the HAQ in the analyses 
described in chapter 6. We showed in that chapter that the functionality was becoming 
worse despite a decrease in the disease activity. This was probably the effect of joint 
destruction or an increasing age (28). Therefore we cannot recommend to use the 
HAQ as an evaluation instrument. More research is needed to know whether patient 
self-assessed joint counts are also subject for response shifts. 
A part of the rationale for using patient reported outcomes in the evaluation of 
RA patients was the comments on the low inter-observer variability of the DAS28, and 
in particular the joint counts. However conflicting results can be found on the inter-
observer variability of the joint counts. Salaffi et al.(29) showed a good exact 
agreement for absence and presence of joint swelling of 69% to 87%, dependent on the 
joints assessed. In a study by Walsh et al.(30) it was shown that the joint counts were 
consistent between observers with interclass correlation coefficients of 0.71 for 
swollen joints, 0.95 for tender joints and 0.99 for the DAS28. From these studies, it can 
be concluded that the DAS28 is a reliable instrument for measuring disease activity 
and therapeutic responses in patients with RA. 
 In summary, when a patient self-reported measure instead of an objective 
measure is used in the evaluation of drug effectiveness, response shifts bias the 
outcomes of the ratings. Results of patient self-reported outcomes have to be 
interpreted with care when comparing valuations of health given by different patients 
and within patients over time. It seemed not possible to correct for response shifts. 
Therefore, an objective measure like the DAS28 seemed more appropriate to use as a 
monitoring instrument.  
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The objective of this thesis was to explore the value and the validity of data collected in 
daily clinical practice for drug evaluation and cost-effectiveness studies, using data 
collected on TNFα blocking agents in rheumatoid arthritis. First, the need for and 
value of information from daily clinical practice was researched. Because the use of 
patient self reported measures could be very convenient to evaluate drug therapy in 
daily clinical practice, its was researched whether these measures could substitute 
more objective measures like the disease activity score.  
 
First a review was performed (Chapter 2) of the published pharmaco-economic data 
that was used by authorities in several countries to support their decision regarding 
reimbursement of TNFα blocking agents for RA. It was shown that a wide variety of 
pharmaco-economic model structures and data input was used for several pharmaco-
economic modeling studies, leading to a wide range of cost-effectiveness ratios 
(€26000 to €164000 per QALY gained). For these and other reasons, the external 
validity of pharmaco-economic models in general is questioned by reimbursement 
authorities in several European countries but also in the Netherlands. In Chapter 3, 4 
and 5 the external validity of data input and model assumptions was studied by 
comparison with data from daily clinical practice. 
In Chapter 3, the efficacy of anti-TNFα agents for RA patients was compared 
between RCTs and daily clinical practice. We showed that in daily practice, patients 
had a lower disease activity and anti-TNFα agents were less effective. However, the 
effects of anti-TNFα agents were similar in RCTs and practice when analyzing the 
daily clinical practice patients who had a disease activity high enough to be eligible for 
the trials. 
In Chapter 4 the three anti-TNFα agents were compared in daily clinical 
practice on major outcomes like, disease activity, functionality, quality of life and 
costs. Furthermore, drug survival was addressed as well as changes in dosages of anti-
TNFα and co-medication use. It was shown that that adalimumab and etanercept are 
more or less equal and favorable compared to infliximab in the first year of treatment. 
The relatively low dose of infliximab as analyzed in this study is thought to be the 
explanation for the difference in effectiveness compared to adalimumab and 
etanercept. 
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An important assumption in most of the RA pharmaco-economic models was 
that rheumatologists adhere to the stopping rule for anti-TNFα treatment in case of a 
non-response at 3 months. Whether rheumatologist do adhere to this stopping rule 
was addressed in Chapter 5. Furthermore, the consequences on disease activity, 
functionality, quality of life and costs were compared between patients who were and 
were not treated according to the guidelines. Several variations on the present 
guideline were modeled, for finding the best ratio between successfully and 
unsuccessfully treated patients. It was shown that adherence to the present Dutch 
guidelines for treatment with anti-TNFα for RA patients was low. Coming with equal 
costs all alternative strategies would result in more responders than theoretical full 
adherence with the guideline would do. However, ‘continuation in case of partial 
response’ would reveal the least unsuccessfully treated patients. A continuation rule 
based on at least 0.6 DAS28 improvement at three months is therefore recommended. 
Together, the results of Chapters 3, 4 and 5 illustrated that treatment of RA 
patients with anti-TNFα blocking agents in daily clinical practice was different from 
what was expected from the performed RCTs and the guidelines developed on the 
basis of the RCTs. Data from a daily clinical practice registry can be used to get insight 
in the actual use and realized effects of medications in daily clinical practice, in 
contrast to the controlled setting of a RCT. Furthermore, data from clinical practice 
can be used to estimate the impact on the budgets in health care by implementing a 
new intervention in daily clinical practice. 
To collect data in daily clinical practice on a large scale, a valid and easy to use 
evaluation instrument is needed. It was recently suggested to use patient self-reported 
measures to monitor patients and to evaluate results from therapy. However, a 
possible problem with self-reporting instruments is the occurrence of response shifts. 
In Chapter 6 the occurrence of the response shift phenomenon in RA was studied by 
testing the hypothesis that later in the disease course the perception of health would 
be better than one would expect on the basis of the disease activity of the patient, 
compared to shortly after diagnosis. It was shown that the perception of health by the 
patient can be different with equal disease activity, depending on the moment in the 
disease course. Furthermore the results indicated that self-reported measures on 
functionality, disease activity and general health cannot substitute measures of disease 
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activity in RA in longitudinal studies and, subsequently, both are needed to be 
measured. 
Some authors suggest that it is possible to correct for response shifts by valuing 
the different situation within the same reference frame. In the research described in 
Chapter 7, patients were asked to re-rate, with a then-test, the baseline health state 
(before the start with anti-TNFα) from the current perspective after three months of 
treatment. Then, at three months, both the baseline state and the three months state 
are valued with the same internal standard and the prospectively measured change 
was calculated with those ratings. However, this study showed that using the then-test 
as a baseline measure, might lead to the paradoxical result that clinical non-
responders increase significantly on a self-reported measure.  
Although patient reported measures could be more convenient to use in large 
daily clinical practice registries, they cannot substitute objective measures of disease 
activity like the DAS28. It was shown that response shifts occurred and greatly 
confounded the outcomes of the patient-self-reported ratings. It was not possible to 
correct for response shift. In RA patients, the DAS28 seems at present the best 
instrument to use in the monitoring and evaluation of effectiveness in daily clinical 
practice. 
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Reumatoïde artritis (RA) is een chronisch ontstekingsziekte van voornamelijk de 
gewrichten. De ziekte wordt gekenmerkt door gewrichtsontstekingen en schade aan 
bot en kraakbeen. Als het gevolg daarvan worden patiënten met RA beperkt in hun 
dagelijks functioneren en hebben ze een verminderde kwaliteit van leven. 
Patiënten met RA worden meestal behandeld met een combinatie van 
geneesmiddelen. Zo is een behandeling met één van de zogenaamde ‘Disease 
Modifying Anti-Rheumatic Drugs’ (DMARDs) in de regel noodzakelijk. Daarnaast 
gebruiken veel patiënten een ontstekingsremmer zoals een ‘Non-steroidal 
Inflammatory Drug’ (NSAID). Corticosteroïden kunnen daarnaast gebruikt worden 
om de ziekteverschijnselen snel te onderdrukken. 
De meeste DMARDs zijn niet specifiek voor de behandeling van RA 
ontwikkeld, maar bleken bij toeval ook voor de behandeling van RA een gunstig effect 
te hebben. De afgelopen 10 jaar zijn er echter nieuwe geneesmiddelen ontwikkeld die 
meer specifiek zijn voor reuma, geïnspireerd op het vermeende ontstaansmechanisme 
van RA. Deze middelen blokkeren de werking van de cytokine TNFα en worden dan 
ook TNFα blokkerende middelen genoemd. In Nederland kunnen er drie varianten 
voorgeschreven worden, adalimumab, etanercept en infliximab, die ieder net iets 
anders werken. 
Een behandeling met TNFα blokkerende middelen is relatief duur: ongeveer 
€1000 per maand. Het aantal patiënten dat een TNFα blokkerend middel is snel 
gestegen. Er wordt geschat dat momenteel 37% van alle RA patiënten in Nederland 
één van TNFα blokkerende middelen gebruikt. In het jaar 2006 stonden zowel 
adalimumab als etanercept in de top 10 van geneesmiddelen die in Nederland qua 
kosten het meest gestegen waren ten opzichte van het jaar daarvoor. Dit is 
waarschijnlijk als gevolg van een forse stijging van het aantal patiënten in combinatie 
met de hoge prijs van deze middelen. 
Omdat we als maatschappij samen het zorgbudget moeten opbrengen in de 
vorm van verzekeringspremies die, om de solidariteit niet in gevaar te brengen, voor 
iedere burger betaalbaar moeten blijven is een doelmatige inzet van dergelijke 
geneesmiddelen vereist. Een doelmatige inzet wordt bereikt als hogere kosten worden 
gecompenseerd door een betere effectiviteit (de kosteneffectiviteitratio) in vergelijking 
met het meest gangbare, of eerst beste, alternatief. In Nederland zijn farmaceutische 
bedrijven verplicht om gegevens aan te leveren over de effectiviteit, kosten en 
doelmatigheid van hun nieuwe geneesmiddel. Deze gegevens worden beoordeeld door 
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het College voor Zorgverzekeringen (CVZ) en vervolgens voorzien van een advies aan 
de minister over de inzet en vergoeding van deze nieuwe middelen.  
De doelmatigheid wordt veelal onderzocht parallel aan een gerandomiseerde 
gecontroleerde studie (RCT) of aan de hand van modellering op basis van de 
resultaten van een RCT. In Hoofdstuk 2 wordt er een overzicht gegeven van de 
gepubliceerde farmaco-economische data die gebruikt is door verschillende 
autoriteiten in verschillende landen om een besluit te nemen over vergoeding van 
TNFα blokkerende middelen. Dit hoofdstuk toont dat er een grote variëteit was in 
gebruikte model structuren en gebruikte data, wat leidde tot een grote variëteit in 
kosteneffectiviteitsratio’s. 
Er is echter op het moment veel discussie over het feit op welke manier 
gegevens over doelmatigheid verzameld moeten worden. Moet dit in een 
gecontroleerde onderzoekssetting waar je het effect van het middel geïsoleerd kan 
bestuderen of in de dagelijkse praktijk waar het middel uiteindelijk gegeven zal 
worden? Het eerste gedeelte van dit proefschrift gaat over het gebruik van gegevens 
die in de dagelijkse praktijk verzameld zijn vergeleken met gegevens uit een RCT. 
We hebben hiertoe een registratie opgezet van het gebruik van TNFα 
blokkerende middelen in 10 verschillende Nederlandse ziekenhuizen. We noemen 
deze registratie het DREAM (Dutch Rheumatoid Arthritis Monitoring) register. Alle 
patiënten met RA die in die 10 ziekenhuizen gestart zijn met één van de TNFα 
blokkerende middelen zijn structureel gevolgd. Patiënten werden iedere drie maanden 
gezien door een onderzoeksverpleegkundige. Er werd dan geregistreerd wat ze precies 
aan geneesmiddelen gebruikten, waarom het gebruik gewijzigd of gestopt werd en 
welke bijwerkingen er eventueel optraden. Daarnaast werd er geregistreerd wat het 
niveau van ziekteactiviteit, functionaliteit en kwaliteit van leven was. Deze gegevens 
zijn gebruikt voor 4 van de 6 hoofdstukken uit dit proefschrift. 
 In Hoofdstuk 3 is de effectiviteit van de drie TNFα blokkerende middelen zoals 
aangetoond in de RCT’s vergeleken met de effectiviteit zoals die gemeten is in de 
dagelijkse klinische praktijk. Alle RCT’s zijn verzameld middels een systematisch 
literatuur onderzoek. Gegevens uit het DREAM register zijn gebruikt om de 
effectiviteit van TNFα blokkerende middelen in de dagelijkse praktijk te bepalen. Uit 
deze vergelijking bleek dat in de dagelijkse praktijk TNFα blokkerende middelen aan 
patiënten met een mildere ziekte werd gegeven dan in de RCTs werd gedaan. De 
effectiviteit was in de dagelijkse praktijk ook minder dan men op basis van de RCT 
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zou verwachten. Echter, als we in de dagelijkse praktijk die groep met patiënten 
selecteerden die volgens hun ziekteactiviteit aan de RCT mee hadden mogen doen, 
dan was de effectiviteit wel nagenoeg gelijk aan de effectiviteit gemeten in de RCT. 
 In Hoofdstuk 4 zijn de drie TNFα blokkerende middelen onderling vergeleken 
wat betreft de daling van ziekteactiviteit, de verbetering van functionaliteit en kwaliteit 
van leven en de gemaakte kosten over een heel jaar. Verder werd er een vergelijking 
gemaakt in de duur van het gebruik, de doseringen en de wijzigingen hierin en het 
gebruikt van co-medicatie. Er werd aangetoond dat adalimumab en etanercept 
vergelijkbaar waren wat betreft hun effectiviteit en dat ze allebei beter waren dan 
infliximab. Bij patiënten die met infliximab behandeld werden, werd vaker de 
dosering opgehoogd en sneller geheel gestopt met de behandeling dan bij patiënten 
die met adalimumab of etanercept behandeld werden. 
 Een belangrijke aanname in de meeste farmaco-economische modellen zoals 
beschreven in hoofdstuk 2 is dat een behandeling met één van de TNFα blokkerende 
middelen wordt gestaakt als het na drie maanden niet effectief is gebleken. Dit is 
tevens een richtlijn voor het gebruik in de dagelijkse praktijk. In Hoofdstuk 5 is 
onderzocht in hoeverre reumatologen zich houden aan die richtlijn. Verder is ook 
onderzocht wat de consequenties waren voor de ziekteactiviteit, functionaliteit en 
kosten van het niet naleven van de richtlijn.  
 Het bleek dat reumatologen zich vaak niet hielden aan de richtlijn, dat wil 
zeggen in 70% van alle patiënten die geen effect lieten zien op drie maanden (en dus 
hadden moeten stoppen volgens de richtlijn) werd de behandeling gecontinueerd. 
Echter bij 40% van deze patiënten werd er na zes maanden wel effect waargenomen. 
Dit geeft aanleiding om te denken dat het in sommige gevallen gerechtvaardigd is om 
de richtlijn flexibel toe te passen. Uit verdere modellering van verschillende scenario’s 
bleek dat de beste balans gevormd wordt tussen het percentage succesvol en 
onsuccesvol behandelende patiënten als je alleen die patiënten behandeld die op drie 
maanden op z’n minst een matige response laten zien.  
 Op basis van de bevindingen kunnen we concluderen dat er in de dagelijkse 
praktijk een mildere patiënten populatie werd behandeld welke resulteerde in een 
minder groot effect dan je op basis van RCTs had kunnen verwachten. Daarnaast 
werd gevonden dat doseringen opgehoogd werden waar dit nodig wordt geacht door 
de behandelend arts en dat de richtlijn flexibel werd toegepast. Hiermee illustreren we 
het nut van een registratie van de dagelijkse praktijk. De data die verzameld worden in 
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zo’n registratie geven een indruk van de mate waarin een nieuwe interventie gebruikt 
wordt door de artsen, bij welke patiënten ze het gebruiken, in welke dosering en 
hoelang. Deze gegevens kunnen vervolgens weer gebruikt worden om te bepalen hoe 
zwaar het gebruik van de nieuwe interventie zal drukken op het zorg budget. 
 
Om de effectiviteit van geneesmiddelen te evalueren in de dagelijkse praktijk heb je 
een meetinstrument nodig die valide is, maar tegelijkertijd ook makkelijk in het 
gebruik. Op dit moment worden patiente met RA meestal geavlueerd met een 
ziejteactiviteits score, de DAS28. Dit is een score die bestaat uit een combinatie van 
het aantal gezwollen en pijnlijke grewrichten uit 28 getelde gewrichten, de 
bloedbezinking (acute phase eiwitten) en een globale inschatting van de gezondheid 
door de patient. Deze DAS28 wordt echter becritiseerd omdat er veel variaties zit 
tussen degene die de gewrichten scoort op swelling of pijn en het kost veel tijd om 
hetm af te nemen. Omdat het is aangetoont dat patient gerapporteerde uitkomsten net 
zulke goede waarden geven als bijvoorbeeld de DAS, maar ze wel veel gemakkelijker 
zijn in het bruik, wordt er voorgesteld om alleen nog maar patient gerapporteerde 
uitkomsten te gebruiken. Hoofdstuk 6 en 7 gaan over de (on)mogelijkheid van het 
gebruik van een patient gerapporteerde uitkomsten in the evaluatie van rheuamtoide 
arthritis.  
Een probleem bij het gebruik van patient gerapporteerde maten is het optreden 
van een response shift. Dit is het fenomeen dat iemand dezelfde gezondheidstoestand 
op een ander moment anders waardeert zonder dat daar objectieve redenen voor zijn. 
Een verklaring hiervoor die in de literatuur wordt genoemd en waar wij op 
aangesloten hebben, is dat iemands referentiekader in de tijd kan veranderen.  
 In Hoofdstuk 6 wordt eerst aangetoond dat dit response shift fenomeen 
optreedt bij patiënten met RA. We hebben laten zien dat patiënten met RA na 
ongeveer een half jaar na de diagnose aangeven dat ze een betere kwaliteit van leven 
hebben dan dat op basis van de mate van ziekteactiviteit verwacht zou kunnen worden 
in vergelijking met hoe ze hun kwaliteit van leven ten tijde van de diagnose 
waardeerden.  
 Er zijn mensen die suggereren dat het mogelijk is om voor zo’n response shift 
fenomeen te corrigeren door de patiënt te vragen een eerdere gezondheidstoestand 
opnieuw te waarden vanuit een veranderd referentiekader. Daarom werden patiënten 
die behandeld werden met TNFα blokkerende middelen gevraagd om na drie 
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maanden hun gezondheidtoestand van voor de start met deze geneesmiddelen 
opnieuw te waarden, maar nu met hun huidige inzichten. Dit heeft als gevolgd dat 
zowel de baseline meting als de 3-maanden meting met hetzelfde referentiekader 
werden beoordeeld. Echter, de resultaten lieten een paradox zien waarin patiënten die 
klinisch gezien verslechterd waren toch op een subjectieve maat significant aangaven 
verbeterd te zijn.  
 We concluderen daarom uit deze twee hoofdstukken dat bij RA patiënten het 
response shift fenomeen optreedt in het waarderen van hun eigen gezondheid en dat 
hier niet voor valt te corrigeren. Daarom adviseren we om de effectiviteit van een 
behandeling te volgen bij een individuele patiënt op basis van een objectieve maat 
zoals die reeds in de reumatologie bestaan zoals de DAS28. 
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